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I. INTRODUCTION 
 
 
Heavy metals are well known to cause adverse effects in living organisms.  At 
both high and low concentrations, heavy metals disrupt the normal functioning of various 
systems including the cardiovascular, respiratory, and central nervous systems.  Because 
of the serious overt effects of high concentrations of heavy metals to the populations, 
many organizations such as the World Health Organization (WHO) and the 
Environmental Protection Agency (EPA) have set standards, restrictions, and 
recommendations as to the amount of heavy metals an individual should be exposed to.  
These set levels while low, may not encompass the sub-toxic concentrations that can 
cause deleterious effects.  A better understanding of how sub-toxic concentrations affect 
the population could either confirm the set levels or require them to be reevaluated and 
lowered.  Therefore, the question is, “how do these metals affect the organism?”  The 
purpose of this study is to determine how “long-term” exposure to sub-toxic 
concentrations of mercury or manganese affects the functioning of the dopamine 
transporter. 
Individuals are exposed to toxic metals through a variety of ways.  Naturally 
occurring processes, certain occupations, waste sites, and accidents can all lead to 
increased contact, absorption and toxicity.  The extent of toxicity an individual may 
experience is partly dependent upon the metal, dose, and route of exposure, and partly 
dependent on the individual affected.  Characteristics, such as age (children and the 
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elderly have been shown to be more susceptible to toxins), genetics, and current or 
developing disease states impact how an individual will react to the metal exposure. 
Volcanic eruptions, erosion, occupations such as those in the thermometer and 
dry-cell battery industries, and dentistry are all routes of mercury exposure (Levine, 
2003; Tchounwou et al., 2003).  Individuals may also be exposed to mercury through 
dental amalgams and a diet of fish (Aschner et al., 2000; Levine, 2003).  Other 
populations that the Agency for Toxic Substances and Disease Registry (ATSDR) 
consider to be at an increase risk of toxicity due to mercury exposure are those living 
close to a former mercury mining site, recycling facility, and municipal or medical 
incinerator (Patrick, 2002).  Waste sites from industrial dumping and the burning of coal 
increases the environmental mercury content which also increase the amount of exposure 
to the population (Patrick, 2002; Levine, 2003).   
Exposure to manganese can also occur through a variety of methods.  Individuals 
employed in welding, mining, and steel manufacturing occupations are among those at 
risk for elevated manganese exposure and its harmful effects (Di Lorenzo et al., 1996; 
Crossgrove & Zheng, 2004; Kitazawa et al., 2005).  The antiknock agent, 
methylcyclopentadienyl manganese tricarbonyl (MMT), and fertilizers and pesticides 
containing manganese increase the environment’s and individual’s exposure levels to 
manganese (Crossgrove & Zheng, 2004). Waste sites, such as Tar Creek, are also a 
means for increased manganese exposure and toxicity.  According to a news release from 
the National Institute of Health in July of 2004, “Tar Creek is a residential area in 
Northeastern Oklahoma that is heavily contaminated with metals from mining waste. The 
principal pollutants are lead, cadmium, zinc, iron and manganese (NIH news release 
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2004).”  Manganese exposure also occurs naturally through ingestion of certain food such 
as whole grains and nuts (Greger, 1999). 
The dopamine transporter, a plasma protein, is responsible for terminating 
dopamine’s actions (Sorkina et al., 2003).  Through the regulation of the dopamine 
transporter, the entire dopaminergic system can be affected because of this transporter’s 
effect on the neurotransmission of dopamine.  The dopamine transporter in turn can be 
regulated by substrates, proteins such as alpha-synuclein, oligomerization, and transport 
into and out of the plasma membrane.  The effects of manganese and mercury on the 
dopamine transporter have also been studied and reported, with manganese studies being 
more numerous and on going.  In contrast, the most recent report on the effects of 
mercury on the dopamine transporter, as determined through a search of PUBMED with 
key words “dopamine transporter” or “dopamine uptake” and “mercury,” was in 1997 by 
Wu, Coffey and Reith.  This may reflect the finding that manganese specifically affects 
the dopaminergic system, while mercury’s effects appear to be more general. 
I.A. Objective of Study 
 
The objective of this study is to determine the effects of long-term exposure to 
sub-toxic concentrations of mercury and manganese on the dopamine transporter 
function.  Studies aimed at measuring [3H]dopamine uptake and [3H]GBR-12935 binding 
to the dopamine transporter expressed in the cell membrane will provide the opportunity 
to see how the functioning of the transporter is affected by low concentrations of these 
metals.  
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II. LITERATURE REVIEW 
 
II.A. Mercury  
The toxic effects of mercury have been observed over hundreds of years.  During 
the Roman era, mercury intoxication was observed in the slaves mining the Spanish 
Almaden mine (Asano et al., 2000).  This mine is currently still one of the dominant 
mines, having produced 236 tons of mercury in 2000 (Hylander & Meili, 2003).  Mercury 
intoxication reportedly was experienced in the year 752 by the builders of the giant 
bronze Buddha, which is coated with a mixture of gold, tin and mercury (Asano et al., 
2000).  Another group of working individuals, those in the fur and felt hat-making 
industries in the 17th century also experienced mercury intoxication (Asano et al., 2000). 
More recent outbreaks of mercury toxicity occurred at Minamata Bay, Niigata, 
Japan, Iraq and along the Amazon River Basin.  The Minamata Bay and Niigata, Japan 
mercury toxicity outbreaks occurred from eating fish with high levels of mercury.  
Industrial dumping of wastes in the water supplies caused a bioaccumulation of mercury 
in the fish, which then affected the humans and animals that ate the fish (Gochfeld, 2003; 
Castoldi et al., 2001).  These individuals were diagnosed with Minamata Bay disease, a 
disorder characterized by symptoms such as visual, hearing, and other sensory 
impairment, muscle weakness and mental deterioration (Castoldi et al., 2001).  In Iraq, 
mercury poisoning occurred after grain that had been treated with pesticide containing 
mercury was made into bread and eaten (Castoldi et al., 2001).  Mercury toxicity also 
occurred along the Amazon River Basin due to gold mining operations, deforestation and 
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damming of rivers (Asano et al., 2000; Gochfeld, 2003).  All of these actions cause an 
increase in mercury levels in fish, which are then consumed by the indigenous people 
(Gochfeld, 2003).   
II.A.i. Characteristics of Mercury 
Mercury, a known toxicant, is ubiquitous in the environment and naturally exists 
in three forms: elemental, inorganic and organic (Tchounwou et al., 2003; Levine, 2003).  
Elemental mercury, also known as metallic mercury, has been used in thermometers and 
dental amalgams (Langford & Ferner, 1999; Patrick, 2002).  It has a melting point of       
-38.87°C and while it is not absorbed well from the gastrointestinal tract, when the 
vapors are inhaled, this form of mercury easily crosses into the circulatory system from 
the lungs (Tchounwou et al., 2003).  Inorganic mercury salts have many uses.  A few of 
these uses include(d) some medicines, skin lightening creams among various other 
products such as antibacterials and explosive detonators (Langford & Ferner, 1999; 
Tchounwou et al., 2003).  This form of mercury has a low absorption rate when ingested 
(7-15%) (Patrick, 2002), however extended exposure to mercury salts can lead to CNS 
damage (Tchounwou et al., 2003).  The third form of mercury, organic mercury, is 
believed to be the most toxic of the three forms (Patrick, 2002).  Two examples of 
organic mercury are ethylmercury, a component of thimerosal (used to preserve 
vaccines), and methylmercury.   
II.A.ii. Central Nervous System 
The central nervous system (CNS) is one of the main targets of mercury 
accumulation and damage.  This metal’s effects on the CNS are well known and 
numerous (Tchounwou et al., 2003; Gasso et al., 2001).  Some of these detrimental 
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effects include disruption of neuronal migration (Tchounwou et al., 2003), neuronal 
degeneration (Castoldi et al., 2001), and demyelination (Patrick, 2002). Mercury is 
capable of harming the blood-brain barrier by damaging the cerebral microvascular 
endothelial cells that compose this important barrier (Papp et al., 2005).  Ca2+-channels, 
neurotransmitter turnover, and nerve conduction are also affected by mercury (Papp et 
al., 2005).  High dose mercury exposure can cause the cerebellum and limbic structures 
to undergo morphological and biochemical changes in both adult and developing central 
nervous systems (Vicente et al., 2004; Costa et al., 2004).  Lesions can be found in this 
area, as was seen in individuals diagnosed with Minamata Bay disease (Costa et al., 
2004).   
  However, there are still questions about mercury’s mechanism(s) of toxicity 
(Bucio et al., 1995; Shanker & Aschner, 2001).  Questions still needing to be answered 
include: what is the primary cellular target (Bertossi et al., 2004)?  While some authors 
report that mercury primarily affects astrocytes, others argue that the primary targets are 
neurons (Bertossi et al., 2004).  Another question that needs to be addressed is, what is 
mercury’s effect(s) on the differentiation of the blood brain barrier (Bertossi et al., 2004)?   
II.A.iii. Mercury and the Dopaminergic System 
While not a specific target of mercury, the dopaminergic system is still affected 
by its toxicity.  Mercury increases the extracellular levels of dopamine through inhibiting 
synaptic uptake of this neurotransmitter (Crinnion, 2000).  It is hypothesized that this 
action may be due to the inhibitory effects mercury has on Na+, K+-ATPase which is 
believed to play a role in catecholamine uptake (Rajanna & Hobson, 1985).   Increases in 
dopamine release have been reported after mercury treatment (Faro et al., 2001).  
 7
Extracellular levels of dopamine metabolites, 3,4,-dihydroxyphenylacetic acid (DOPAC) 
and homovanillic acid (HVA), are decreased in cases of mercury exposure, which may be 
explained by the decrease of dopamine synthesis that occurs (Faro et al., 2001).   
It has also been recognized that prenatal exposure to mercury affects the 
dopamine system.  Altered locomotor activity was reported from studies examining the 
outcomes from prenatal mercury exposure (Castoldi et al., 2001).  Additionally, 
individuals who are prenatally exposed to mercury may be at risk for developing 
pathological conditions such as Parkinson’s disease or Alzheimer’s disease later in life 
because of these early dopaminergic changes (Castoldi et al., 2001). 
II.A.iv. Cellular Mechanism of Toxicity 
Whether the primary cellular target of mercury is astrocytes or neurons, mercury 
can disturb cellular function through a variety of mechanisms.  Altering calcium ion 
homeostasis (Juarez et al., 2005; Patrick, 2002), depleting antioxidants, especially 
glutathione (Bucio et al., 1999), and perturbing mitochondrial membrane potential 
(Juarez et al., 2005) have all been reported upon mercury exposure.  Disturbed glutamate 
activity (Juarez et al., 2005) and enhanced formation of reactive oxygen species (Ercal et 
al., 2001) are cellular effects of mercury toxicity.   Mercury has been shown to inhibit 
Na+-K+-Cl- cotransport (Jacoby et al., 1999), and to decrease ATP levels (Fonfria et al., 
2005) as well.  These effects, both individually and in combination, can all lead to cell 
death through apoptosis and/or necrosis.  
In astrocytes, mercury inhibits the uptake of the excitatory neurotransmitters 
glutamate and aspartate (Shanker & Aschner, 2001; Aschner et al., 2000).  Mercury 
further increases the extracellular levels of these amino acids by inducing their release 
 8
from intracellular stores (Shanker & Aschner, 2001; Castoldi et al., 2001).  Such an 
increase in extracellular glutamate and aspartate can cause the N-Methyl-D-Aspartate 
(NMDA) receptors to overactivate, which could possibly cause the cell to enter into the 
excitotoxic cascade (Aschner et al., 2000; Juarez et al., 2005).  Neurodegeneration 
(Castoldi et al., 2001), neuronal lesions (Aschner et al., 2000), and DNA damage (Juarez 
et al., 2005) may be accelerated or develop in response to these excitotoxic effects. 
Due to the high affinity, approximately, 10-15-10-23 of mercury for thiol groups, 
the major chemical reaction of mercury is with this group (Castoldi et al., 2001; Aschner 
et al., 2000).  Glutathione levels, in particular, have been reported to be decreased due to 
mercury.  This decrease of glutathione results in a reduced cellular defense against 
oxidative damage (Shanker & Aschner, 2001).  Decreased levels of glutathione also 
provides an opportunity for the formation and accumulation of reactive oxygen species 
(ROS) along with the potential for an increase in damage done by other toxins from the 
environment (Shanker & Aschner, 2001; Vicente et al., 2004; Crinnion, 2000).  
 
Figure 1: Mercury can cause apoptosis and necrosis.  Hypothesized drawing 
of how mercury can cause apoptosis and necrosis (Kim and Sharma, 2004). 
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One action of reactive oxygen species (ROS) is to induce cell death, and at least 
one of mercury’s effects, disrupting calcium homeostasis, can lead to an increased 
production of ROS (Kim & Sharma, 2004).  Further depletion of glutathione (Patrick, 
2002) and enhanced lipid peroxidation and DNA damage (Stohs & Bagchi, 1995) can 
occur due to ROS formation.  Neuronal degeneration and cellular damage due to 
increased ROS production can lead to cell apoptosis and/or necrosis (Figure 1) (Kim & 
Sharma, 2004; Juarez et al., 2005; Castoldi et al., 2001). 
 Mercury in the nervous system can disrupt calcium homeostasis by causing an 
increase in intracellular calcium (Stohs & Bagchi, 1995; Castoldi et al., 2001).  
Depending on the mercury species, the resulting intracellular calcium concentrations may 
come from both an influx from extracellular spaces and intracellular stores (Gasso et al., 
2001; Stohs & Bagchi, 1995).  Kim and Sharma (2004) reported this change in calcium 
homeostasis occurred prior to an increase in reactive oxygen species production as ROS 
production could be eliminated by calcium antagonists.    
Mercury can cause a decrease in the membrane potential of mitochondria, an 
organelle that accumulates mercury (Kim & Sharma, 2004; Toimela & Tahti, 2004).  
This decreased membrane potential allows for an efflux of Ca2+ out of the mitochondria 
along with decreased Ca2+ uptake into the mitochondria (Atchinson & Hare, 1994).  This, 
together with the release of cytochrome c, can cause the cell to enter apoptosis (Kim & 
Sharma, 2004; Toimela & Tahti, 2004). 
II.A.v. Peripheral Effects 
Mercury exposure can have effects on many body systems.  The renal, 
respiratory, cardiovascular, gastrointestinal, hepatic, immune, reproductive and dermal 
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systems have all been reported to have negative responses after mercury exposure.  The 
renal system, particularly the epithelium cells of the proximal tubules, is one of the main 
mercury targets (Carranza-Rosales et al., 2005; Aleo et al., 2005).  Signs of 
nephrotoxicity that have developed due to mercury exposure include reduced blood flow 
and glomerular filtration, and albuminuria (Van Vleet & Schnellmann, 2003; Crinnion, 
2000).  The respiratory system is affected when mercury particles are inhaled.  Mercury 
in the lungs can cause respiratory distress, pneumonitis (Graeme & Pollack, 1998), and 
acute chemical bronchitis (Asano et al., 2000).  Another system affected by mercury is 
the cardiovascular system.  Cardiovascular effects due to mercury exposure include 
decreased variability of heart rate, which is associated with heart failure (Grandjean et al., 
2004; De Jong & Randall, 2005), and arterial hypertension caused by vascular smooth 
muscle contraction (Golpon et al., 2003).  An increased risk for cardiovascular disease 
and progression of carotid atherosclerosis has been reported in individuals with mercury 
exposure (Patrick, 2002).  Because mercury is corrosive to the mucous membranes, oral 
burning and stomatitis may occur when mercury is ingested (Graeme & Pollack, 1998).  
Ulceration and hemorrhage can occur in the gastrointestinal tract with this route of 
mercury exposure (Jacoby et al., 1999; Stohs & Bagchi, 1995).  Autoimmune 
abnormalities (Ben-Ozer et al., 2000), decreased fertility (Horsted-Bindslev, 2004), and 
dermatitis (Levine, 2003) have also been reported from exposure to mercury. 
II.A.vi. Symptoms of Mercury Toxicity  
The symptoms and effects of mercury toxicity are vast and depend upon: the 
nature of metal, the route of administration, length and dose of exposure, species type, 
gender, and age (Vicente et al., 2004; Bertossi et al., 2004; Blaxill et al., 2004).  All of 
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the symptoms that occur with mercury toxicity are too numerous to mention here, 
therefore the focus will be on the central nervous system.  These symptoms include 
tremor, insecurity, loss of memory, fatigue, excitability, insomnia, hallucinations, and 
irritability (Graeme & Pollack, 1998; Langford & Ferner, 1999; Levine, 2003).  Seizures, 
decreased strength, hearing loss, constricted visual field and ataxia are other central 
nervous system symptoms reported from mercury exposure (Graeme & Pollack, 1998; 
Levine, 2003; Castoldi, et al., 2001).   
II.A.vii. Diseases Associated with Mercury 
 Mercury exposure has been associated with autoimmune disease (McCabe et al., 
2005), scleroderma (Hess, 2002), autism (Bernard et al., 2001), Alzheimer’s disease and 
Parkinson’s disease (Vicente et al., 2004).  While mercury may directly cause these 
diseases, it may also trigger or exacerbate current but unrecognized conditions such as 
genetic factors (Bernard et al., 2001).  It has been reported that autistic children have 
been exposed to elevated mercury and they have atypical mercury metabolism (Blaxill et 
al., 2004).  The dysfunctions mercury causes in the immune, sensory, neurological, motor 
and behavioral systems are similar to those found in autism (Bernard et al., 2001).  
 Mercury levels are found to be elevated in the blood of patients with Alzheimer’s 
disease.  In one study, mercury was found to be more than two fold higher in the blood of 
patients with Alzheimer’s disease than in the control group (Hock et al., 1998).  Blood 
mercury levels of the individuals with Alzheimer’s disease were found to be 
2.64 ± 0.38µg/l while the control group that consisted of individuals without any 
psychiatric disorders levels were 1.09 ± 0.12 µg/l (Hock et al., 1998).  Postmortem brain 
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tissue from patients with Alzheimer’s disease shows elevated levels of mercury (Hock et 
al., 1998; Olivieri et al., 2000). 
II.B. Manganese  
Manganese was first recognized as a neurotoxicant in France in 1837.  Workers 
grinding manganese ore developed symptoms such as drooling, loss of facial expression, 
unsteady gait and muscular weakness (Normandin & Hazell 2002; Jankovic, 2005).  
Since then, several more incidences of manganese poisoning have occurred.  Cases of 
toxicity have been documented concerning workers exposed to pesticides and fungicides 
containing manganese, welders, miners, and individuals drinking water with high 
manganese content (Bowler et al., 2006; Zatta et al., 2003). 
II.B.i. Characteristics and Normal Functional Role 
Although also a transition metal, manganese differs from mercury in that it is an 
essential element important for normal brain development and functioning (Takeda, 
2003).  Manganese has eleven oxidation states from -3 to +7 (Takeda, 2003), with Mn+2, 
+3, and +4 being physiologically relevant (Tiffany-Castiglioni & Qian, 2001).   Manganese 
can be found in foods such as whole grains, nuts, legumes and tea (Greger, 1999).  
According to the FDA’s daily food composite, the average adult man ingests 2.7mg of 
manganese while the average woman consumes 2.2mg of manganese (Greger, 1999). 
Under normal conditions, manganese has many important functions.  Besides 
being required by the brain for proper development and functioning (Takeda, 2003), 
manganese is important for connective tissue and bone formation as well as bone 
maintenance (Roth et al., 2002).  Animals deficient in manganese have been shown to 
develop skeletal abnormalities that are thought to occur due to a reduction in 
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proteoglycan synthesis, impaired osteoblast and osteoclast activities and/or an alteration 
in insulin and insulin-like growth factor (Keen et al., 1999).  The metabolism of amino 
acids, carbohydrates and lipids are other roles manganese performs while present in 
normal concentrations (Slikker et al., 2004).   
Manganese functions through activating, regulating, being a co-factor for or 
binding to many different enzymes.  A few of the enzyme families that require 
manganese include: oxidoreductases, transferases, hydrolases (Slikker et al., 2004) and 
peroxidases (Stredrick et al., 2004).  For example, the enzymes that manganese associates 
with and functions through are mitochondrial superoxide dismutase (MnSOD), arginase, 
pyruvate carboxylase and glutamine synthetase.  Through its participation with the 
mitochondrial superoxide dismutase, manganese plays a role in antioxidant activity 
(Zhang et al., 2003).  Manganese is a co-factor for arginase, an enzyme found in the liver 
which plays a role in the production of urea (Crossgrove & Zheng 2004).  Pyruvate 
carboxylase, another mitochondrial enzyme, participates in gluconeogenesis by 
converting pyruvate to oxaloacetate and requires manganese as a co-factor (Crossgrove & 
Zheng 2004; Siegel et al., 1999).  Glutamine synthetase, a metalloprotein found in glia, is 
bound and regulated by manganese (Takeda 2003; Crossgrove & Zheng 2004). 
Alterations in glutaminase activity would alter the concentration of glutamine, the 
primary precursor for glutamate, either increasing the synthesis of glutamate or 
decreasing the metabolism of glutamate (Takeda, 2003).   Manganese may also activate 
decarboxylases and kinases (Di Lorenzo et al., 1996).   
Manganese actions have been shown to be bimodal.  At low concentrations, 
manganese is not toxic and functions as mentioned previously as an essential element.  
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However, at higher concentrations manganese causes toxicity and cell death (Keller et al., 
2005).   According to the National Academies’ Institute of Medicine, the adequate intake 
level of manganese for adult males is 2.3mg/day and for females, 1.8mg/day, while the 
upper intake level for manganese in the adult is 11mg.   These values are adjusted with 
pregnancy and the different stages of childhood (Dobson et al., 2004).  Manganese in 
water has a lowest observable adverse effect level (LOAEL) estimated to be 4.2mg 
Mn/day (Greger, 1998).  Additionally, it has been reported that chronic manganese 
exposure to levels >1-5mg Mn/m3 in air can cause adverse effects (Dobson et al., 2004). 
II.B.ii. Central Nervous System  
Manganese can enter the brain by crossing the choroid plexus, the blood brain 
barrier, and/or possibly the olfactory nerve (Normandin & Hazell, 2002; Takeda, 2003).  
This uptake into the brain through the blood brain barrier and choroid plexus occurs 
either via transferrin-mediated endocytosis and/or non-transferrin mediated process (Zatta 
et al., 2003).  Transferrin, a protein in blood that carries iron, can also bind manganese 
(Verity, 1999; Zatta et al., 2003).  The non-transferrin processes include: calcium 
channels, Na+/Ca2+ exchanger, active calcium uniporter and Na+/Mg2+ antiporter (Takeda, 
2003).  Manganese is taken up into the brain more rapidly when it is not in transferrin 
bound form (Zatta et al., 2003).  Although not yet proven in humans, it is possible that 
manganese may be able to by-pass the brain barriers and enter and accumulate in the 
brain by crossing transneuronally through the olfactory nerve (Jankovic, 2005; 
Normandin & Hazell 2002).  This method of manganese entry into the brain has been 
demonstrated in rats exposed to manganese intranasally (Yu et al., 2003). 
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Once manganese passes the brain barriers, regardless of route, it specifically 
targets and accumulates in the areas of high dopaminergic content (Andersen et al., 
1999).   Specifically, the nigrostriatal dopaminergic system has been found to be affected 
by excessive manganese (Kitazawa et al., 2005, Tomas-Camardiel et al., 2002).  The 
caudate putamen, globus pallidus, substantia nigra, and subthalamic nuclei, all structures 
of the basal ganglia, accumulate the highest concentrations of manganese (Dobson et al., 
2004).  The choroid plexus has also been found to sequester and accumulate manganese 
(Ingersoll et al., 1995; Zheng, 2001).   
II.B.iii. Manganese and Dopaminergic System 
As mentioned above, the nigrostriatal dopaminergic system is selectively targeted 
by manganese (Kitazawa et al., 2005).  The targeting of this area may be related to the 
reuptake and/or concentration of dopamine since both a dopamine reuptake inhibitor, 
cocaine, and a dopamine depleter, reserpine, inhibited manganese concentrating in the 
central nervous system (Ingersoll et al., 1999).  Manganese treatment in experimental 
animals does not appear to cause structural changes in the nigrostriatal dopamine neurons 
(Normandin & Hazell 2002).  However, an irreversible loss of dopaminergic neurons 
does occur due to chronic manganese exposure (Slikker et al., 2004; Yu et al., 2003).   
The effect of manganese on dopamine content is still uncertain.  Reports 
documenting a significant decrease, no measurable changes, or an increase in dopamine 
concentrations have all been published (Bonilla & Prasad, 1984; Ali et al., 1985; Eriksson 
et al., 1987; Baek et al., 2003).    Baek et al. (2003), attribute these differences to 
variations in experimental design or the “multifactorial nature” of manganese.  Others 
have reported that manganese causes biphasic changes in dopamine levels, where at low 
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concentrations manganese causes an increase in dopamine levels and at higher 
concentrations a decrease in dopamine levels (Tomas-Camardiel et al., 2002).  Another 
study reported no changes in dopamine levels, but an increase in GABA levels with low 
concentration manganese treatments (Gwiazda et al., 2002).  Similar to the discrepancies 
of manganese effects on dopamine, the dopamine metabolites DOPAC and HVA have 
been reported to be either unchanged (Ingersoll et al., 1995; Takeda, 2003) or reduced 
(Normandin & Hazell, 2002). 
Manganese has been reported to effect dopamine synthesis, storage, and release.  
The rate limiting step of dopamine synthesis, tyrosine hydroxylation, has shown to be 
reduced by manganese exposure (Higashi et al. 2004; Hirata 2002).  This would explain 
the decrease in dopamine content because a slower rate at this stage of dopamine 
synthesis would decrease the amount of L-DOPA formed, which is the immediate 
precursor of dopamine.  Another explanation for the decreased dopamine content due to 
manganese exposure may be an alteration in dopamine storage (Ingersoll et al., 1995).  
Manganese has been reported to cause the release of dopamine from nerve terminals 
(Takeda, 2003), and to enhance the formation of dopamine reactive quinones (Stokes et 
al., 2000).  This latter process which also produces toxic free radicals occurs through 
auto-oxidation of dopamine by the transfer of one electron (Takeda, 2003; Zatta et al., 
2003).   
II.B.iv. Mechanisms of Cellular Injury 
Manganese is transported into astrocytes through a high affinity, high capacity 
transport system (Normandin & Hazell, 2002).  Functional changes such as alteration of 
the glycolytic enzyme glyceraldehydes-3-phosphate dehydrogenase, production of nitric 
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oxide, and decreased GSH levels have been reported to occur in astrocytes due to 
manganese exposure (Normandin & Hazell, 2002; Desole et al., 1994).  Additionally, 
blocking voltage-dependent calcium channels and disrupting the release and transport of 
the neurotransmitters glutamate and GABA have been observed in response to 
manganese (Takeda, 2003; Fitsanakis & Aschner, 2005; Zatta et al., 2003).  Hirata et al. 
(1998) have reported that manganese causes internucleosomal DNA fragmentation, 
suggesting that part of the neurotoxic effects produced by manganese may be due to 
apoptosis. 
Once inside the astrocytes, manganese actively concentrates in the mitochondria 
via the mitochondrial Ca+2 uniporter (Gavin et al., 1999; Gunter et al., 2005).  Here 
manganese binds to the inner membrane of the mitochondria (Malecki, 2001; Galvani et 
al., 1995), and then perturbs mitochondrial function through numerous mechanisms 
(Kitazawa et al., 2005; Zhang 2003; Roth et al., 2002).  Mitochondrial Ca2+ transport 
kinetics are affected by manganese disruption of calcium homeostasis.  This can lead to 
decreased oxidative phosphorylation, decreased ATP and an inhibition of mitochondrial 
electron transfer with accumulation of reactive oxygen species (Verity, 1999; Kitazawa et 
al., 2005).  Manganese inhibits mitochondrial respiration, causes a reduction of 
mitochondrial enzymatic activities (Hirata et al., 1998, Galvani et al., 1995), and a loss of 
mitochondrial membrane potential (Malecki, 2001).  Secondary to these effects on the 
mitochondria, manganese causes apoptosis which is considered to be one of the 
mechanisms of its neurotoxicity (Malecki, 2001; Stredrick et al., 2004).   
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II.B.v. Peripheral Effects 
There are reports of the liver and lungs being negatively affected by manganese.  
The liver concentrates manganese and maintains the homeostasis of manganese in the 
body (Zhang et al., 2003; Yu et al., 2003).  When the liver is damaged, manganese 
elimination may be delayed or decreased which results in an increased amount of time 
that the body is exposed to this metal.   This in turn provides manganese a longer chance 
to accumulate and exhibit its toxic effects (Crossgrove & Zheng 2004).  
Lung damage occurs when manganese is inhaled.  Manganese inhalation has 
caused cytotoxic effect on lung epithelial cells, and it has been connected with respiratory 
irritant effects (Pascal & Tessier 2004).  The manganese accumulated in the lungs is 
characterized by slow uptake and elimination process which means lung tissue has a long 
exposure to manganese (Yu et al., 2003).  This may result in extensive damage to the 
lung tissue.   
II.B.vi. Symptoms of Manganese Toxicity 
It may take several months or years for the symptoms of manganese toxicity to 
appear (Keen et al., 1999).  Symptoms of manganese exposure include behavioral 
changes (Kitazawa et al., 2005), depressed appetite, growth depression (Greger, 1998), 
and a reduction in motor function (Gwizada et al., 2001).  Tremors, lethargy, muscle 
rigidity and slowed movements are also reported by individuals affected by manganese 
toxicity (Ingersoll et al., 1995).  Psychiatric symptoms resembling schizophrenia have 
been observed and documented as well in individuals who have been chronically exposed 
to manganese via inhalation (Greger, 1998). 
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II.B.vii. Diseases Associated with Manganese Toxicity 
Manganism, a disorder that produces symptoms similar to idiopathic Parkinson’s 
disease, results from chronic exposure to manganese (Di Lorenzo et al., 1996; Archibald 
& Tyree, 1987).  Behavioral changes including anorexia, insomnia, weakness and apathy 
are among the first symptoms of manganism (Zatta et al., 2003; Zhang et al., 2003).   The 
next stage of symptoms is similar to those of Parkinson’s disease and may include 
disorientation, memory loss, anxiety, rigidity, and tremor (Zatta et al., 2003; Archibald & 
Tyree, 1987).  Dystonia and gait disturbances appear in the last, most severe stage of 
manganism (Zatta et al., 2003).  Even after removal from manganese exposure, once 
manganism has been established, this disease will continue to progress to its severest 
form (Zatta et al., 2003).   
The data on manganese’s contribution to the development of Parkinson’s disease 
is contradictory.  Some studies have reported manganese exposure as a risk factor for 
Parkinson’s disease (Sava et al., 2004), while other studies can not make this connection 
(Baek et al., 2003).  Other authors have proposed that pre-parkinsonian conditions such 
as sub-threshold neurodegeneration may be exacerbated by manganese effects (Gwiazda 
et al., 2002). This metal may also enhance brain physiological aging leading to an 
increased risk of developing Parkinson’s disease (Gwiazda et al., 2002; Zatta et al., 
2003). 
It is recognized that other disease states can make an individual more susceptible 
to the effects of manganese.  Individuals with an iron deficiency, Alagille syndrome, 
chronic liver failure and/or receiving long-term parenteral nutrition (TPN) are at an 
increased risk of developing manganese toxicity (Crossgrove & Zheng, 2004; Normandin 
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& Hazell, 2002).  The hepatobilary route is the main route for manganese excretion; 
therefore in cases where the liver is not functioning properly such as with Alagille 
syndrome, chronic liver failure and TPN, manganese is not being excreted as it should.  
This leads to an increase in the body’s manganese levels, which can then become toxic 
(Crossgrove & Zheng, 2004; Normandin & Hazell, 2002). 
II.C. Dopamine Transporter 
 
 
 
 
 
 
 
Figure 2: Schematic of human DAT.  Pitchforks on extracellular loop between transmembrane 
domains 3 and 4 represent possible sites for glycosylation (Masson, et al., 1999).   
 
The dopamine transporter (DAT) is an important component of the dopaminergic 
system.  By regulating the amount of dopamine found extracellularly, the DAT has a role 
in all of the actions mediated by dopamine such as movement, pleasure, reinforcement 
and behavior (Kahlig & Galli, 2003; Mortensen & Amara, 2003; Bannon, 2005).  In turn, 
the DAT can be regulated through a change in expression levels or an alteration in its 
function in response to substrates, inhibitors, psychostimulants such as cocaine and 
amphetamine, and interactions with other proteins.  It is recognized that some of these 
changes in the DAT may be associated with or play a role in some disease states such as 
Parkinson’s disease and drug addiction (Bannon, 2005). 
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The DAT which is solely expressed on dopamine-synthesizing neurons (Bannon, 
2005) can be found on the soma and dendrites in the substantia nigra and ventral 
tegmental area and on axonal terminals in the striatum (Miranda et al., 2004; Maiya & 
Mayfield, 2004).  This plasmalemmal protein is composed of 620 amino acids with 
twelve transmembrane domains with both the carboxy- and amino-termini located 
intracellularly (Reith et al., 1997).  The DAT structure contains several sites 
intracellularly for possible phosphorylation (Melikian, 2004) and at least three sites for 
N-glycosylation on the extracellular loop between transmembranes 3 and 4 (Chen & 
Reith, 2000; Miranda et al., 2004) (Figure 2).  It has been shown that glycosylation at 
these sites is associated with cell surface expression and important for the proper 
functioning of the DAT (Torres et al., 2003; Li et al., 2004).  Studies have shown that the 
DAT becomes oligomerized via symmetrical crosslinking between cysteine residues 
early in its synthesis, and this formation is continued through the intracellular movement, 
or trafficking, of the DAT (Torres et al., 2003; Maiya & Mayfield, 2004; Mortensen & 
Amara, 2003).  These same authors along with others have reported that oligomerization 
has an important role in the proper trafficking of the DAT into and out of the cell 
membrane (Torres et al., 2003; Maiya & Mayfield, 2004; Mortensen & Amara, 2003; 
Miranda et al., 2004). 
II.C.i. Dopamine Transporter Function 
The primary role of the DAT is to move dopamine across the cell membrane back 
into the cell after its release into the extracellular space.  Through this re-uptake action, 
DAT regulates dopamine neurotransmission (Jaber et al., 1997; Uhl, 2003) and reduces 
the amount of dopamine synthesis needed (Kahlig & Galli, 2003).  The DAT, like the 
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other members of the Na+/Cl- dependent transporter family, transports sodium and 
chloride ions with their substrates (Zahniser & Doolen, 2001), because they need the 
energy from the Na+ gradient created by the (Na+/K+)-ATPase to move the substrates 
against their concentration gradients (Masson et al., 1999).  Specifically, the DAT moves 
two sodium ions and one chloride ion with each dopamine molecule.  At physiological 
pH dopamine is protonated, resulting in the net movement of two positive charges for 
each molecule of dopamine translocated (Maiya & Mayfield, 2004; Sonders et al., 1997).   
II.C.ii. Dopamine transporter trafficking 
 
Figure 3: DAT trafficking pathway.  A schematic representation of the DAT 
trafficking pathway (adapted from Torres et al., 2003).   
 
 The efficiency with which DAT can remove dopamine from the extracellular 
space depends in part on the number of DAT at the cell surface (Sorkina et al., 2003; 
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Kahlig et al., 2004).  Therefore, the trafficking of the transporter into and out of the cell 
membrane plays an integral part in DAT functioning (Figure 3).   
 The rough endoplasmic reticulum (RER) is the site of DAT protein synthesis 
(Hersch et al., 1997; Kimmel et al., 2001).  From here, the DAT is shuttled to the Golgi 
complex where it undergoes posttranslational modifications (Kimmel et al., 2001; Hersch 
et al., 1997).  One posttranslational modification thought to occur in the Golgi complex is 
glycosylation (Hersch et al., 1997; Sorkina et al., 2003).  The DAT is then transported to 
the smooth endoplasmic reticulum of the dendrites and axons before it arrives at the 
plasma membrane (Kimmel et al., 2001; Hersch et al., 1997).  When the DAT receives a 
signal to re-enter the cell, it has been shown to do so through a process dependent on 
clathrin and dynamin (Sorkina et al., 2003; Granas et al., 2003).  It first is transported to 
early endosomes by clathrin-coated pits (Daniels & Amara, 1999).  The next step in the 
DAT life cycle depends on the cell system DAT is expressed in (Mortensen & Amara, 
2003).  Some studies have shown that after internalization DAT is recycled back to the 
plasma membrane in PC12 cells (Loder & Melikian, 2003), while others have shown that 
in the MDCK cell system DAT is degraded after internalization (Daniels & Amara, 
1999). 
II.C.iii. Regulating the Dopamine transporter 
 Regulation of the DAT can occur through altering the transporter’s function or its 
trafficking to the plasma membrane (Figure 3).  According to Mortensen and Amara 
(2005) and Sidhu et al., (2004), the activity of the transporter is most commonly 
regulated through its movement into and out of the plasma membrane.  Through 
increasing or decreasing the number of transporters on the cell surface, the amount of 
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extracellular dopamine re-captured is affected along with all of the systems and reactions 
that dopamine interacts with.  The substrates, inhibitors, and proteins that interact with 
DAT can regulate its function and expression. 
 
Figure 4: Possible ways the DAT may be regulated.  Inhibitors, substrates, phosphorylation, 
hetero-and autoreceptors, along with membrane potential, oligomerization and interaction 
with other proteins can regulate the dopamine transporter expression on the cell surface 
(adapted from Mortensen and Amara, 2003). 
 
Alpha-synuclein, a presynaptic protein, can regulate the amount of DAT located 
on the plasma membrane through complexing with the transporter.  This complexing 
between these two proteins in turn affects DAT function, dopaminergic 
neurotransmission, and the levels of intracellular dopamine (Wersinger et al., 2003).    
Lee et al. (2001) have reported that alpha-synuclein causes the DAT to cluster on the cell 
membrane which causes an increase in dopamine uptake.  This in turn enhances the 
chances of apoptosis due to excess dopamine (Lee et al., 2001). 
 Phorbol esters and kinases regulate the DAT.  Phorbol esters are able to regulate 
the number of DAT on the cell surface by activating PKC.   Upon exposure to phorbol 
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esters, the DAT is down-regulated through a clatherin-mediated endocytosis pathway 
(Chi & Reith, 2003; Daniels & Amara, 1999).  This results in a decreased uptake of 
dopamine.  Another way that DAT is regulated is through kinases.  Phosphorylation and 
dephosporylation of the DAT by kinases controls the cycling of the transporter between 
internalization and the plasma membrane (Piccini, 2003).   
 Dopamine can affect the function of the dopamine transporter.  Dopamine can 
directly down-regulate and indirectly upregulate the dopamine transporter function 
(Gulley & Zahniser, 2003).  These effects of dopamine on the DAT are concentration-
dependent.  High concentrations have been shown to cause down-regulation of the 
dopamine transporter, while low concentrations of dopamine cause an up-regulation (Chi 
& Reith, 2003; Gulley & Zahniser, 2003). 
Other stimuli that can produce DAT changes, such as alterations in kinetics, 
substrate transport capacity, and the number of DAT include: cocaine, amphetamine, 
MPP+, receptor occupation of dopamine presynaptic receptors, and second messenger 
signaling (Gulley & Zahniser, 2003; Batchelor & Schenk, 1998; Moron et al., 2003). 
II.C.iv. Diseases Associated with DAT 
Because the DAT does have such a critical role in dopaminergic 
neurotransmission, in disease states that are found to have an altered or improper 
dopamine tone, the DAT becomes one of the suspects for causing or supporting the 
disease state.  Schizophrenia, Parkinson’s disease, drug addiction (Kahlig & Galli, 2003; 
Moron et al., 2003), mental retardation (Loupe et al., 2002) and ADHD (Bannon, 2005) 
are among the disease states that have been found to, or are thought to have improper 
dopaminergic tone.  Both in Parkinson’s disease and ADHD, there have been studies 
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showing increases in DAT localization and functioning (Storch et al., 2004; Vernier et 
al., 2004; Bannon, 2005).  Other diseases/disorders, such as dementia with Lewy bodies, 
Wilson’s disease, Machado-Joseph disease, Lesch-Nyhan disease, and Gilles de la 
Tourette’s syndrome, have observed a difference in DAT expression, but have yet to 
uncover the effects, if any, of these differences (Bannon, 2005). 
II.D. SUMMARY 
Mercury and manganese are found everywhere in the environment, exposing 
everyone to their effects.  These effects depend on the metal, species, dose, and exposure 
time among many other factors.  It is recognized that high doses of mercury and 
manganese are toxic, and because of this, agencies such as the World Health 
Organization and Environmental protection agency have set limits suggesting the 
maximum amount an individual should be exposed to.  While these limits may be 
appropriate for acute exposure, their accurateness for long term exposures of sub-toxic 
concentrations is yet unknown and need further investigating. 
Adding to the toxicity of mercury and manganese are their effects on the 
dopaminergic system.  While it is recognized that these metals affect the dopamine 
transporter, the mechanism of how they do this has not yet been determined.  The 
purpose of this project is to determine how long term exposure to sub-toxic 
concentrations of mercury and manganese affect the dopamine transporter. 
II.D.i. Hypothesis 
The hypothesis for this study is that mercury and manganese in their chloride 
forms will reduce the dopamine transporter functionality.  This reduction in functioning 
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may possibly be due to an increase in the internalization of the dopamine transporter as 
compared to the control group. 
II.D.ii. Aims 
The aims for this project include: 
● Determining the toxic threshold concentrations of mercury and manganese. 
● Determining the affect of mercury and manganese on the functioning of the dopamine 
transporter through: 
•determining the amount of [3H]DA taken up by treated cells 
•determining the amount of [3H]GBR-12,935 binding to DAT on the cell surface 
•determining the kinetics of [3H]GBR-12,935 binding to the DAT 
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III. MATERIALS and METHODS 
III.A. Cell Culture 
 SK-N-SH cells (A.T.C.C., Manassas, VA) were grown in complete media 
(R.P.M.I. 1640, 1X without L-glutamine (Mediatech, Inc., Herndon, VA), supplemented 
with 10% Fetal Bovine Serum (Atlanta Biologicals, Norcross, GA), and 1% Penicillin-
Streptomycin (Mediatech, Inc. Herndon, VA) in 25cm2 cell culture flasks with vented 
caps (Corning Incorporated, Corning, NY).  They were maintained in the incubator at 
37°C in a humidified (5% CO2) environment.  Media was changed twice a week with 
5mL of fresh complete media that had been warmed in the 37°C water bath for forty-five 
to sixty minutes.  The flasks were then returned to the incubator.   
 Cells were subcultured every seven days.  For this process, new flasks with 5mL 
of warmed complete media were placed in the incubator to allow the carbon dioxide to 
equilibrate in the media while the cells were being trypsinized.  Trypsinization of the 
cells was conducted as follows.  Trypsin (0.25%) + EDTA(0.1%)  in HBSS without 
calcium, magnesium, or sodium bicarbonate (Mediatech, Inc, Herndon, VA) was placed 
in the warm water bath for forty-five to sixty minutes, and then 1.5mL was added to each 
flask of cells after the old media was carefully removed.  The flasks were allowed to sit 
for 15-20 minutes and then if necessary gently agitated to finish removing the cells.  3.5-
4.5mL of complete media was then added to these flasks to terminate the trypsinzation 
process and gently mixed together by pipetting the solution up and down.  1mL of this 
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cell suspension was then added to the new flasks containing fresh complete media, gently 
mixed by swirling, and placed back into the incubator.  
 Cells were plated following a similar process.  900µL of warmed fresh complete 
media was added to a clear 24 well flat bottom cell culture plate (Costar®, Corning, Inc., 
Corning, NY). The plate was then placed in the incubator to equilibrate the media with 
CO2 while the cells were being trypsinized in the same manner as above.  5mL of 
complete media was added to the trypsinized cells, gently mixed by pipetting up and 
down, and then 100µL of this cell suspension was added to each well of the plate.  The 
plates were then placed back into the incubator for at least 24 hours before any 
experimentation.  All cell work was done with sterile techniques. 
III.B. Metal Treatments 
 The metal solutions were made with RPMI, and then autoclaved before use.  All 
of the metal solutions were made in 21X concentrations so that the final concentration in 
the well or flask would be the concentration desired.  For example, for the 10µM 
manganese chloride treatment in a twenty-four well plate, a 210µM concentrated metal 
solution was made so when 50µL of the metal solution was added to the well with 
1000µL of cells/media, the final concentrations would be 10µM (210X (50/1050)=10). 
 Twenty-four hours after the cells were plated or split into flasks, one of the metal 
solutions or control would be added either to the plate or flask of cells, depending on 
which experiment was being run, and then mixed by gentle oscillation. 
III.C. LDH Assay 
 The CytoTox 96® Non-Radioactive Cytotoxicity Assay by Promega (Madison, 
WI) was used to determine the percent viability of the cells after treatment with the heavy 
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metals.  This assay measures the amount of lactate dehydrogenase (LDH) present in the 
cell media which can then be used to determine the amount of cells that have died.  Upon 
addition of the Substrate Mix-Assay Buffer mixture, the following chemical reactions 
occur in the wells during the CytoTox 96® Non-Radioactive Cytotoxicity Assay: 
LDH 
NAD+ + lactate → pyruvate + NADH 
 
Diaphorase 
NADH + INT → NAD+ + formazan (red) 
 
First, the LDH released from the cells that have died catalyzes the reaction between 
NAD+ and lactate from the Substrate Mix to form pyruvate and NADH.  For the second 
reaction, this latter product, NADH, then reacts with INT via the diaphorase from the 
Substrate Mix to form NAD+ and formazan red.  The amount of red formazan product 
formed from this reaction is directly proportional to the amount of cell death, and this can 
be measured with a standard 96 well plate reader (CytoTox 96® Non-Radioactive 
Cytotoxicity Assay Technical Bulletin No. 163). 
III.C.i. Method 
 Cells were plated as described above, allowed to sit for at least 24 hours, and then 
treated with HgCl2 or MnCl2.  The sample size was four, with at least three replicates, 
and each well was tested in duplicate.  The SK-N-SH cells were treated with 50µL of in-
well final concentrations of 0.1, 1.0, 10.0 or 50.0µM mercuric chloride (HgCl2), 1.0, 2.0, 
5.0, or 10.0µM manganese chloride (MnCl2), or RPMI (control) for four different time 
points (24, 48, 72, or 96 hours).  At the end of the designated treatment time, the CytoTox 
96® Non-Radioactive Cytotoxicity Assay was conducted essentially as described in the 
Promega technical bulletin.  In order to determine the amount of spontaneous release, 
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5µL of each well was pipetted into a clear 96 well plate.  To each well 45µL of complete 
media was added to bring the volume up to 50µL.  The remaining media from the twenty-
four well plate was removed with a transfer pipet and discarded.  To each well, 150µL of 
Lysis Solution was then added in order to measure the total amount of LDH released.  
The plates were then placed back in the incubator for forty-five minutes.  At the end of 
this time period, 900µL of complete media was added to each well to bring the total 
volume back up to the original volume of 1050µL.  5µL was again pipetted out of these 
wells into the remaining wells of the 96 well plate and then 45µL of complete media was 
added to the wells.  Next, 50µL of Substrate Mix (12mL of thawed Assay buffer (Tris-
buffered tetrazolium dye (INT-chloride), and Triton-X-100) mixed with one bottle of 
Substrate mix (lyophilized diaphorase, lactate, and NAD+)) was added to each of the 96 
wells.  The plates were then protected from light and placed on a plate shaker for thirty 
minutes.   50µL of Stop Solution (1M acetic acid) was then added to each well and the 
absorbance was read with the Synergy HT  Multi-Detection Microplate Reader (Bio-
TEK® Instruments, Inc., Winkooski, VT) with KC4  software (Bio-TEK® Instruments, 
Inc., Winkooski, VT) at 490nm. 
 Data was calculated by dividing the spontaneous release by the spontaneous plus 
total release of LDH.  This difference was then subtracted from one and multiplied by 
one hundred to obtain percent viability:  
[ ] Viability % 100 
release LDH Totalrelease LDH sSpontaneou
release LDH sSpontaneou1 =×
+
−  
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III.D. Caspase 3/7 Assay 
 Promega’s Apo-ONE® Homogeneous Caspase-3/7 Assay (Madison, WI) was 
used to determine the amount of cells that had entered into the apoptotic pathway after 
treatment with the heavy metals.  Because caspases play an important activator role in 
apoptosis through cleaving proteins that lead to cytoplasmic blebbing and DNA 
fragmentation, measuring the amount of caspase activity in the wells of the treated cells 
is an effective way to determine the degree of apoptosis in the sample.  In this assay, the 
activities of caspase-3 and -7 are measured by detecting the amount of fluorescent 
product formed after the Caspase-3/7 Reagent (1:100 mixture of Caspase Substrate Z-
DEVD-R110 (100X): Apo-ONE® Homogenous Caspase-3/7 Buffer) has been added and 
mixed in the wells.  The Caspase Substrate contains the profluorescent substrate, Z-
DEVD-R110, which is cleaved by the caspases present in the lysed cell contents to form 
a fluorescent product, rhodamine 110, upon excitation at 499nm.  
 
Figure 5: Caspase-3/7 Reaction.  A depiction of the reaction that occurs in Promega’s Apo-ONE® 
homogenous Caspase-3/7 Assay kit upon addition of Apo-ONE® Reagent to the sample.  The 
caspases-3 and-7 cleave the Z-DEVD portion of the profluorescent Z-DEVD-R110 which results in 
the fluorescent R110 product on the right side of the reaction.  The fluorescent activity can be 
detected by a plate reader with excitation and emission parameters set at 499 and 521, respectively. 
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The amount of fluorescence produced can be read by a plate reader and is in proportion to 
the amount of caspase-3/7 activity (Apo-ONE® homogeneous Caspase-3/7 Assay 
Technical Bulletin No. 295). 
III.D. i. Method 
 The Apo-ONE® Homogeneous Caspase-3/7 Assay was carried out according to 
the directions supplied with the kit.  The cells were plated into a Microtest 96-well black 
assay plate to prevent fluorescent “bleeding” into adjoining wells with a clear bottom and 
lid (BD Biosciences, Franklin Lakes, N.J.).  Both blanks and controls were run with each 
treatment, and each treatment consisted of a sample size of four with replicates run in 
quadruplicate.  Treatments consisted of 1.0µM HgCl2, 10.0µM MnCl2, or control 
treatment for 48 and 96hrs.  At the end of the treatment time, 100µL of Apo-ONE® 
Caspase-3/7 Reagent (100µLof Caspase Substrate: 9900µL of the Apo-ONE® Caspase-
3/7 Buffer®).  The plate was then covered and placed on a plate shaker for thirty minutes.  
The plate was then read with the plate reader at an excitation wavelength of 485 ± 20nm 
and an emission wavelength of 530 ± 25nm. 
 The data was calculated by averaging the blanks and subtracting this value from 
both the control and treatment groups.   
III.E. [3H]GBR-12,935 Binding 
 The number of DAT in the plasma membrane affects the efficiency of dopamine 
clearance from the synaptic space.  Therefore, the next step of this project was to 
determine if the treatment of SK-N-SH cells with 10μM MnCl2 or 1μM HgCl2 had an 
effect on the number of DAT in the plasma membrane.  This was accomplished using 
[Propylene-2,3-3H]GBR-12,935 and unlabeled GBR-12,909. GBR-12,935 is a selective 
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inhibitor of the DAT.  In tritiated form, GBR-12,935 binding to the DAT can be inhibited 
by unlabeled GBR-12,909 (Richfield, 1991).  Therefore, GBR-12,909 was used to define 
non-specific binding.  Non-specific binding is the binding that occurs to any site other 
than the dopamine transporter.  The values obtained from non-specific uptake were 
subtracted from total binding (samples without GBR-12,909) to calculate specific 
binding.  
 [3H]GBR-12935 saturation binding curves were also performed to determine the 
Bmax and KD values of binding to the dopamine transporter.  By obtaining the Bmax and 
KD values for the binding of [3H]GBR-12,935 to the dopamine transporter, we are able to 
determine if there is a shift in the number of dopamine transporter sites and/or a change 
in the binding affinity of [3H]GBR-12,935 for the dopamine transporter due to mercuric 
chloride or manganese chloride treatments in the SK-N-SH cell line.   
III.E.i. Method 
 Twenty-four hours after subculturing, cells were randomly treated in the flasks 
with either RPMI (control), 10 µM MnCl2, or 1 µM HgCl2 for 48 or 96 hours.  At the end 
of the exposure times, the treated media was removed, the cells were washed twice with 
1-2mL of RPMI, and then 1mL of trypsin/EDTA was added to the flasks to detach the 
cells from the side of the flask.  This cell suspension was then pipetted into flat top 
microcentrifuge tubes (Fisher Scientific, Pittsburgh, PA) and centrifuged in the Nanofuge 
(Hoefer Scientific Instruments, San Francisco, CA) for 15 minutes to form a cell pellet.  
The supernatant was decanted, and the cell pellets were placed in the -80°C freezer until 
the binding assays were performed. 
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 The cell pellets were then resuspended in 2.5mL of assay buffer (50mM Tris-HCl 
and 120mM NaCl adjusted to pH 7.7).  400µL of this cell suspension was pipetted into 
round bottom 12X75mm polypropylene culture test tubes (Fisher Scientific, Pittsburgh, 
PA) along with either 50µL of assay buffer (total binding) or 50µL of 5µM GBR-12,909 
(Sigma-RBI, St. Louis, MO) (non-specific binding) in duplicate.  Next, 50µL of 40µM 
[3H]GBR-12,935 (Perkin Elmer, Boston, MA) was added to all tubes for a final in-tube 
concentration of 4nM.  The tubes were vortexed using the Fisher Vortex Genie 2  
(Fisher Scientific, Pittsburgh, PA) followed by a sixty minute incubation period at room 
temperature to reach equilibrium.  The binding reaction was terminated by filtration onto 
a Whatman GF/C filter (Whatman Paper Ltd., ) which had been pre-soaked in 0.3% 
polyethyleneimine (PEI) (Sigma Aldrich, St. Louis, MO) using a Brandel Tissue 
Harvester (Gaithersburg, MD).  Filters were washed with ice cold 0.9% NaCl for 15 
seconds and then carefully removed with the filter disks being placed in labeled 
scintillation vials (Daigger, Vernon Hills, IL).  5mL of ScintiVerse  (Fisher Scientific, 
Pittsburgh, PA) was added to each of the vials, which were then capped and vortexed.  
The vials were then counted for five minutes using the Beckman Coulter LS 1801 
scintillation counter (Beckman Coulter Inc., Fullerton, CA).  Non-specific binding was 
subtracted from total binding to calculate the specific DAT-[3H]GBR-12,935 binding. 
 For the saturation curve assays, flasks of cells were treated as mentioned above.  
Each one of these flasks was used for both a [3H]DA uptake assay and a [3H]GBR-12935 
assay.  At the end of the treatment time, the cells were washed twice with RPMI, 
detached from the side of the flask with 1mL of trypsin/EDTA, and then divided into two 
microcentrifuge tubes.  These tubes were then centrifuged for 3-5 minutes.  Once 
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centrifuged and the supernatant was removed, one of the tubes was used immediately for 
[3H]DA uptake assays (method to be described below) while the other tube was stored in 
the -80° freezer to be used for the [3H]GBR-12,935 saturation curve assays at a later date.   
 The pellet of cells for the [3H]GBR-12,935 saturation curve assay was 
resuspended in 30mL of binding buffer after it was thawed.  The rest of the assay was 
carried out as described above with the exception that instead of adding a final 
concentration of 4nM [3H]GBR-12-935, increasing concentrations of [3H]GBR-12935 (1, 
2.5, 5, 10, 25, 50nM-in final concentration) was added to total and non-specific tubes.  
The samples were then harvested as described above. 
 Protein concentrations for each sample were determined using the Bradford 
protein assay method.  The remaining sample from the above study was diluted with 
500µL of assay buffer.  40µL of Dye Reagent Concentrate (Bio-Rad, Hercules, C.A.) was 
added to a clear 96-well plate.  160µL of the samples were then mixed in duplicate with 
the concentrated dye.  The plate also contained eight concentrations of a protein standard 
and a blank sample that was used to compare the samples to.  The plate was incubated at 
room temperature for five minutes and then read with the plate reader at an absorbance of 
595nm. 
 The calculations for pmol/mg protein were conducted using Quick Calcs 
Radioactivity calculator (GraphPad Software, Inc., San Diego, CA) based on specific 
activity of the radioligand.   
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III.F. [3H]DA Uptake 
 In order to determine if the functionality of the DAT in SK-N-SH cells changed 
following 48 or 96 hour exposure to either 1.0µM HgCl2 or 10.0µM MnCl2, [3H]DA 
uptake assays were conducted.  Two concentrations of [3H]DA was used, one low 
(20nM) and one high (200nM), in order to detect if there was a shift in DAT functioning 
between these concentrations.  As mentioned above, half of the flask designated for the 
[3H]DA uptake assay was used for [3H]GBR-12,935 saturation curve binding assays.  
This approach was used so these related aspects could be examined on cells of the same 
passage and from the exact same conditions, thereby making the comparison of data 
stronger. 
III.F.i. Method 
 As described above, after the 48 or 96 hours, the cells were rinsed with warmed 
RPMI to stop the treatment.  The cells were then detached from the flask using 
trypsin/EDTA and split into two microcentrifuge tubes (one to be used for the uptake 
assay and one to be used for the binding assay) and centrifuged for 3-5 minutes. After the 
supernatant was removed, the cell pellet was resuspended in 30mL of uptake assay buffer 
(25mM HEPES, 120mM NaCl, 5mM KCl, 2.5mM CaCl2, 1.2mM MgSO4, 300µM 
ascorbic acid, 1µM pargyline and 2mg/mL D-(+) glucose, supplemented with 50nM 
Nisoxetine to prevent uptake into NET, pH 7.4).  400µL of this cell suspension was then 
added to culture test tubes with either 50uL of assay buffer (total) or 50uL of 50µM 
GBR-12,909 (non-specific; final concentration: 5µM).  50µL of either 200 or 2000µM 
[7,8-3H]DA (Amersham Biosciences, UK; final concentration: 20 and 200µM, 
respectively) was added in duplicate to the total and non-specific tubes.  The tubes were 
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incubated for ten minutes at room temperature and then harvested by filtration under 
reduced pressure on a PEI soaked Whatman GF/C filter using the Brandel Tissue 
Harvester.  The filter discs created were then placed in scintillation vials along with 5mL 
of scintillation cocktail.  The vials were vortexed and then placed in the scintillation 
counter to measure counts per minute in order to determine the amount of [3H]DA taken 
up into the cells.   
 The amount of protein in the sample was determined using the Bradford method 
as described above and used to calculate the amount of uptake per amount protein.  These 
calculations for pmol/mg protein were conducted using Quick Calcs Radioactivity 
calculator based on specific activity of the radioligand.  This value was then divided by 
10 minutes to determine the amount of [3H]DA uptake per minute (pmol/mg 
protein/min.). 
III.G. Statistical Analysis 
 One-way or two-way ANOVAs were calculated on the data for the LDH, 
Caspase-3/7, one-point [3H]GBR-12,935 binding, and two point [3H]DA uptake followed 
by Bonferroni or Dunn’s Multiple Comparison posttest, when appropriate, to determine if 
there was a statistical significance between the means of the various treatments.  A 
nonparametric one-way ANOVA (Kruskal-Wallis test) followed by Dunn’s Multiple 
Comparison posttest was conducted on KD and Bmax values after they were determined 
via nonlinear regression (curve fit) analysis.  A p<0.05 was deemed to be statistically 
significant.  All statistical analysis calculated for this study was done using the computer 
program GraphPad Prism® Version 4.0 for Windows (GraphPad Software, San Diego, 
CA).
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IV. RESULTS 
 
IV. A. LDH Assay 
 An LDH assay was used to determine the effect of MnCl2 and HgCl2 on cell 
viability.  SK-N-SH cells were treated with increasing concentrations of HgCl2 or MnCl2 
for 24, 48, 72 and 96 hours.  Promega’s CytoTox 96® Non-Radioactive Cytotoxicity 
Assay was preformed to calculate the amount of released lactate dehydrogenase in each 
of the samples.  This colorimetric assay is directly proportional to the amount of LDH 
present with absorbance being read at 490nm.  Percent viability values were calculated as 
described above.    
Figure 6: LDH activity in SK-N-SH cells upon various HgCl2 concentrations and exposure times.  
Percent viability was calculated by subtracting from 1, spontaneous release divided by spontaneous 
plus total release, and then multiplying this value by 100%.  Each value represents the mean ± SEM 
of a sample size of four completed in at least triplicate. The data reveals that there is a time 
(p<0.0001), concentration (p<0.0001), and time X concentration effect (p=0.0069) on the viability of 
SK-N-SH cells when treated with increasing concentrations of HgCl2 and increasing the exposure 
times (*p<0.05; **p<0.001 different from control values).   
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 Statistical analysis of the data was conducted using a two-way analysis of 
variance (ANOVA) in order to determine if there was a difference among the varying 
concentrations and exposure times.  With the mercuric chloride treatments, it was 
observed that with increasing concentrations, differences in cell viability were observed 
over various time points when compared to control values (Figure 4).  The results 
following two-way ANOVA demonstrated a significant effect of time (F3,60=4.44; 
p=0.0069), concentration (F4,60=114.36; p<0.0001) and a time X concentration interaction 
(F12,60=5.33; p<0.0001) on cell viability following mercuric chloride exposure.   
 
 
Figure 7: LDH activity in SK-N-SH cells upon various MnCl2 concentrations and exposure times.  
Percent viability was calculated the same as for the HgCl2 values, and then analyzed using a two-way 
ANOVA.  Each value represents the mean ± SEM of a sample size of four completed in at least 
triplicate.  The data demonstrates that there is a significant effect of time (p<0.0001), concentration 
(p=0.0003) and time X concentration (p<0.0001) effect on the SK-N-SH cell line (*p<0.05 different 
from control values).  
 
 Interestingly, the manganese chloride treatments also exhibited a significant effect 
of time (F3,60=8.97; p<0.0001), concentration (F4,60=6.22; p=0.0003) and time X 
concentration interaction (F12,60=4.63; p<0.0001) on SK-N-SH viability (Figure 5).  This 
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is likely due to the trend of the data, since the only point statistically different from 
control was 2.0µM MnCl2 at 48 hours (p<0.05). 
IV.B. Caspase-3/7 Assay 
 Based on the results of the LDH assay, it was determined that 1.0µM HgCl2 and 
10.0µM MnCl2 exposure for 48 and 96 hours would be most appropriate.  While it was 
determined that the SK-N-SH cells were not overtly dying at these concentrations and 
time points, it wasn’t known if these cells may be entering into a slower programmed 
death process, apoptosis.  Therefore, the next step was to determine if 1.0µM HgCl2 or 
10.0µM MnCl2 exposure at 48 and 96 hours increased caspase activity, a sign that the 
cells were entering the apoptosis pathway.  For the detection of caspase-3 and -7 
activities, Promega’s Apo-ONE® Homogeneous Caspase-3/7 Assay was utilized.  
Samples fluoresced in direct proportion to the amount of capase-3/7 activity present, 
which was then measured at an excitation wavelength of 485 ± 20nm and an emission 
wavelength of 530 ± 25nm.  The average blank values were subtracted from the control 
and treatment groups before statistical analysis was preformed on the data. 
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Figure 8: Caspase-3/7 activity in the SK-N-SH cell line after 1.0µM HgCl2 treatment for 48 or 96 
hours.  Data was calculated by subtracting the average blank value (18.7188±1.7188) from the 
control and treatment values, and is expressed as mean absorbance values ± SEM of a sample size of 
four run in quadruplicate.  A one-way ANOVA determined that there was not a significant effect due 
to 1.0µM HgCl2 treatment at 48 or 96 hours (p=0.3255). 
 
Figure 9: Caspase-3/7 activity in the SK-N-SH cell line after 10.0µM MnCl2 treatment for 48 or 96 
hours.  Data was calculated by subtracting the average blank value (18.7188±1.7188) from the 
control and treatment values, and is expressed as mean absorbance values ± SEM of a sample size of 
four run in quadruplicate.  There was not a significant effect due to 10.0µM MnCl2 treatment at 48 
or 96 hours as determined by a one-way ANOVA (p=0.1670). 
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 For both the mercuric chloride and manganese chloride treatment groups, a one-
way ANOVA was preformed to determine the effect of time.  It was found that the 
1.0µM mercuric chloride treatment at 48 and 96 hours did not have a significant effect on 
Caspase-3/7 activity in the SK-N-SH cell line (F3,15=1.255; p=0.3255) (Figure 6).  A 
similar lack of effect was observed with 10.0µM manganese chloride (F3,15=2.006; 
p=0.1670)(Figure 7). 
 The ratio of percent viability per caspase-3/7 activity was calculated to determine 
if the cells that survived the metal treatment had more or less caspase-3/7 activity in 
comparison to the corresponding control groups (Tables 1 and 2). 
Table 1: Caspase-3/7 Activity per %Viability (HgCl2).  48 and 96Hr treatment with 
1.0µM HgCl2 (data represents mean ± SEM for an N=4). 
Treatment 48Hr 96Hr 
Control 0.3480±0.0084 0.3432±0.0503 
HgCl2 0.2929±0.0364 0.4435±0.0869 
 
 A one-way ANOVA (Kruskal-Wallis) was calculated for the comparison of the 
48 and 96 hour control and 1.0µM HgCl2 groups determined there was not a significant 
treatment effect (p=0.4609) on the ratio of caspase-3/7 activity to percent viability. 
Table 2: Caspase-3/7 Activity per % Viability (MnCl2).  48 and 96Hr treatment with 
10.0µM MnCl2 (data represents mean ± SEM for an N=4). 
Treatment 48Hr 96Hr 
Control 0.4094±0.0117 0.3642±0.0210 
MnCl2 0.6542±0.1087 0.3469±0.0134 
 
 One-way ANOVA (Kruskal-Wallis) analysis of the control and 10.0µM MnCl2 
data calculated a significant effect of treatment on the ratio of caspase-3/7 data to percent 
viability (p=0.0347).  Because there was a significant difference, Dunn’s Multiple 
Comparison Test was run after the one-way ANOVA.  This post test determined there 
was not a significant difference between control and MnCl2 treatment groups at 48 or 96 
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hours (p>0.05).  This indicates there was no increase in the amount of apoptosis activity 
in the remaining live cells due to either treatment. 
IV. C. [3H]GBR-12,935 Binding 
 [3H]GBR-12935 binding to the DAT was utilized to determine if the different 
heavy metal treatments would affect the cell surface expression of the dopamine 
transporter.  Because GBR-12,935 binds with high affinity (5.5nM as determine in rat 
striatal membranes) (Andersen, 1987), and specificity, it makes it an appropriate drug to 
label the DAT.  The binding studies were performed after cells were treated in flasks with 
vehicle, 1.0µM HgCl2, or 10.0µM MnCl2 for 48 or 96 hours.  The cells were then 
trypsinized, and centrifuged into a pellet.  The pellet was resuspended in assay buffer and 
incubated at room temperature to equilibrium (60 minutes) with either assay buffer (total 
binding) or 5µM GBR-12,909 (non-specific binding) along with the [3H]GBR-12,935.  
Samples were then harvested on a GF/C filter followed by placement into a vial and then 
scintillation cocktail was added.  The amount of binding was measured by liquid 
scintillation spectrophotometry.  A protein assay was then conducted on the unused 
portion of the sample using the Bradford method.  Data was then calculated and reported 
as pmol/mg protein.  
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Figure 10: The effect of 1.0µM HgCl2 on [3H]GBR-12, 935 binding to the dopamine transporter after 
exposure to the SK-N-SH cell line for 48 and 96 hours.   The data represents an N=4, conducted in 
duplicate ±SEM.  Statistical analysis determined that this concentrations of HgCl2 did not have a 
significant effect on [3H]GBR-12,935 binding to the DAT over 48 and 96 hours (p=0.9053). 
 
 
 
Figure 11: The effect of 10.0µM MnCl2 on [3H]GBR-12,935 binding to the plasma membrane bound 
dopamine transporter.  Binding took place in assay buffer, and this reaction was stopped by washing 
the samples with an ice cold 0.9% NaCl.  The data represents a sample size of four conducted in 
duplicate.  Statistical analysis determined that 10.0µM manganese chloride did not have a significant 
effect on [3H]GBR-12,935 binding to the dopamine transporter at either 48 or 96 hours (p=0.6112). 
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 A one-way ANOVA was preformed on the data to determine if there was a 
significant time effect on the amount of DAT expression as when compared to the values 
calculated for the control groups at each time point.  There were no significant effects of 
HgCl2 on the binding of [3H]GBR-12,935 binding to the DAT in the SK-N-SH cell line 
(p=0.9053) (Figure 8).  The one-way ANOVA calculated on the MnCl2 data also 
determined that 10.0µM MnCl2 did not effect [3H]GBR-12,935 binding to the DAT at 48 
or 96 hours (p=0.6112) (Figure 9). 
The saturation binding curve assays were carried out similarly to the one-point 
[3H]GBR-12,935 binding described above.  One difference is instead of using the whole 
flask for the assay, only one half of the flask was used so that the other half could be used 
for [3H]DA uptake assays.  The other difference is that instead of testing one 
concentration, the saturation binding curve assays utilized six increasing concentrations, 
1, 2.5, 5, 10, 25, 50nM (final in tube concentrations).  Specific [3H]GBR-12,935 binding 
values were calculated as before: Total Binding-Nonspecific Binding=Specific Binding.  
This value was combined with the results from the protein assay on the remaining 
samples to calculate pmol/mg protein values for each of the data points. 
Linear regression was performed on the data after it was plotted (Figures 10 and 
11) using GraphPad prism in order to calculate the KD and Bmax values for each of the 
treatments (see Tables 2 & 3).  Once this was conducted, a one-way ANOVA was 
performed to compare the KD and Bmax values in order to determine if the 48 or 96 hour 
treatments with 1.0µM HgCl2 or 10.0µM MnCl2 caused a change in the dopamine 
transporter binding affinity or capacity. 
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Table 3: Bmax and KD values for [3H]GBR-12,935 binding.    
48Hr treatment with 1.0µM HgCl2 or 10.0µM MnCl2. 
 48 Hr Control 48Hr MnCl2 48Hr HgCl2 
Bmax (pmol/mg protein) 469.9±162 1736±993.3 1592±407 
KD (nM) 8.96±9.20 15.43±19.84 16.73±9.73 
*All values represent the mean ± SEM for an N=4 completed in duplicate. 
 
 
Figure 12: 48 hour saturation [3H]GBR-12,935 binding curves after 1.0µM HgCl2 or 10.0µM MnCl2 
exposure.  Binding was conducted in assay buffer and incubated at room temperature for 60 minutes.  
The samples were harvested onto PEI soaked filters before being transferred to scintillation vials and 
counted.  Above values represent an N=4 conducted in duplicate.  Statistical analysis using a one-way 
ANOVA determined no significance in Bmax (p=0.2106) or KD (p=0.1738) among the control and two 
metal treatments. SEM error bars were omitted for graphical purposes. 
 
The results from the one-way ANOVA Kruskal-Wallis test performed on the 
48hour data determined neither the Bmax nor KD values from the treatments with 1.0µM 
HgCl2 or 10.0µM MnCl2 were significantly different from the 48hour control values for 
these measures (p=0.2106, 0.1738 respectively).   
Table 4: Bmax and KD values for [3H]GBR-12,935 binding. 
96Hr treatment with 1.0µM HgCl2 or 10.0µM MnCl2. 
 96Hr Control 96Hr MnCl2 96Hr HgCl2 
Bmax (pmol/mg protein) 339.4±84.7 260.7±68.6 181.5±68.2 
KD (nM) 7.08±5.44 6.32±5.28 6.89±8.03 
*All values represent the mean ± SEM for an N=4 completed in duplicate.  
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Figure 13: 96 hour saturation [3H]GBR-12,935 binding curves after 1.0µM HgCl2 or 10.0µM MnCl2 
exposure.  Specific binding was determined by subtracting non-specific binding (GBR-12,909) from 
total binding (assay buffer).  One-way ANOVA statistical analysis calculated no significance for 
either the Bmax or KD values due to the either of the metal treatments after 96Hr treatments 
(p=0.1738, 0.6677 respectively).  SEM error bars were omitted for graphical purposes. 
 
The one-way ANOVA Kruskal-Wallis test analysis calculated for the data 
obtained from the 96Hr treatments with 1.0µM HgCl2 or 10.0µM MnCl2 also determined 
there was no significant  difference in the Bmax (p=0.1738) or KD (p=0.6677) values at 
this time point. 
Additional one-way ANOVA calculations were conducted to see if treatment time 
(48Hr vs. 96Hr) had an effect on Bmax and KD values.  Analysis of the HgCl2 data 
determined while there was not a significant treatment difference for the KD value 
(p=0.8137), there was a significant treatment effect of Bmax (p=0.0110) calculated using 
the Kruskal-Wallis test.  A Dunn’s Multiple Comparison test following the one-way 
ANOVA calculated a significant difference between the 48 and 96 hour HgCl2 treated 
groups (p<0.01).  Analysis of 10.0µM MnCl2 and the control groups found no significant 
difference in Bmax (p=0.0877) or KD (p=0.3256) from 48 to 96 hours. 
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IV.D. [3H]DA Uptake  
 Two point [3H]DA uptake assays were conducted to determine if the functionality 
of the DAT had changed due to 48 or 96 hour exposure to 1.0µM HgCl2 or 10.0µM 
MnCl2 and/or if there was a change in function from a low to high concentration of 
[3H]DA.  For the uptake assay, the other half of the flask used for [3H]GBR-12,935 
saturation curve binding assays was used.  The treatment was stopped with two washes of 
warmed RPMI and the cells were detached from the side of the flask using 
trypsin/EDTA.  The cells were then centrifuged for three to five minutes, the supernatant 
removed, and then the cell pellet was resuspended in 30mL of assay buffer.  400µL of the 
cell suspension was then incubated at room temperature with either assay buffer (total 
uptake) or 5µM GBR-12,909 (non-specific uptake) and 20 or 200nM [3H]DA (final in 
tube concentrations) for ten minutes.  At the end of the incubation period, the samples 
were harvested onto GF/C filters and transferred to a vial.  Scintillation cocktail was 
added; the vial was vortexed, and then placed into the scintillation counter.  The Bradford 
method was used to determine the amount of protein in the samples.  All of the data was 
then combined and calculated so values could be reported as pmol/mg protein/min.  
 For statistical analysis, a two-way ANOVA was calculated on the data to 
determine if there was an effect on [3H]DA uptake due to metal treatment, [3H]DA 
concentration, and/or interaction between these variables.  The Bonferroni post test was 
also calculated, so the means of each group analyzed in the two-way ANOVA could be 
compared to each other. 
 The two-way ANOVA calculated on the 48 and 96Hr control and 1.0µM HgCl2 
[3H]DA uptake data determined there was a significant effect of treatment (F3,24=9.11; 
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p=0.0003), [3H]DA concentration (F1,24=19.86; p=0.0002), and interaction of treatment X 
[3H]DA concentration (F3,24=6.16; p=0.0029) in SK-N-SH cells.  The Bonferroni posttest 
calculated no significant difference established between 48 and 96 hour HgCl2 values at 
20 or 200nM [3H]DA (p>0.05 for both concentrations).   
 
Figure 14: 20 and 200nM [3H]DA uptake in SK-N-SH cells after 48 hour exposure to 1.0µM  HgCl2.  
Specific uptake was determined by subtracting non-specific uptake from total uptake.  The Bradford 
method was used to calculate protein values so data could be reported as pmol/mg protein/min.  The 
Bonferroni posttest calculated no significant difference between control and HgCl2 [3H]DA uptake 
values at 20nM [3H]DA.  There was a significant difference in [3H]DA concentration uptake between 
control and HgCl2 groups at 200nM (p<0.01) detected in the SK-N-SH cell line (**p<0.01 different 
from control values). 
  
 The results from the Bonferroni posttest indicated that after 48hour treatment with 
HgCl2 there was a not a significant difference between the control and HgCl2 groups at 
20nM (p>0.05), but a significant difference was detected at 200nM [3H]DA (p<0.01) 
(Figure 14).   
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Figure 15: 20 and 200nM [3H]DA uptake in SK-N-SH cells after 96 hour exposure to 1.0µM  HgCl2.  
Specific uptake was determined by subtracting nonspecific uptake (GBR-12909) from total uptake 
(assay buffer).  The Bradford method was used to determine the amount of protein in each sample so 
values could be reported as pmol/mg protein/min.  A Bonferroni posttest determined there was no 
difference between the control and 96 hour 1.0µM  HgCl2  group at concentration of 20nM [3H]DA 
(p>0.05) or 200nM [3H]DA(p>0.05). 
  
 No significant difference was observed between the 96 hour control and HgCl2 
groups in SK-N-SH cells when means from the [3H]DA uptake assay were compared 
using the Bonferroni posttest (p>0.05 for both 20 and 200nM [3H]DA) (Figure 13).  
Table 5: Summary of Uptake Findings after treatment with  
1.0uM HgCl2 in SK-N-SH cells 
 20nM 200nM 
48 Control vs. 48 HgCl2  no significant difference significant difference (p<0.01)
96 Control vs. 96 HgCl2 no significant difference no significant difference 
  
 Similar statistical calculations were also performed on the MnCl2 data.  Results 
from the two-way ANOVA conducted on the combined 48 and 96 hour data comparing 
the control data to that of 10.0µM MnCl2 treatment determined there was a significant 
treatment (F3,24=9.95; p=0.0002), [3H]DA concentration (F1,24=22.58; p<0.0001), and 
treatment X [3H]DA concentration (F3,24=6.98; p=0.0015) effect on [3H]DA uptake in 
SK-N-SH cells.  The Bonferroni posttest determined there was also a significant 
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difference between 48 and 96 hour MnCl2 values at 200nM (p<0.001), but not at 20nM 
(p>0.05). 
 
 
Figure 16: 20 and 200nM [3H]DA uptake in SK-N-SH cells after 48 hour exposure to 
10.0µM  MnCl2.  Pmol/mg protein/min values were calculated using specific uptake values 
(total uptake-nonspecific uptake) and protein concentrations as determined by the 
Bradford method.  The Bonferroni posttest conducted on this data established there was 
not a significant treatment effect at 20nM [3H]DA (p>0.05), but there is a significant 
treatment effect at 200nM [3H]DA (p<0.05) (*p<0.05 different from control values).   
 
  
 Statistical analysis on the 48 hour control vs. 10.0µM MnCl2 data using a 
Bonferroni posttest determined there was not a significant difference between means at 
20nM [3H]DA (p>0.05).  The same test did determine a significant difference between 
control and MnCl2 values with 200nM [3H]DA uptake (p<0.05) (Figure 14). 
20 200.
0
100
200
300
400
500 Control
MnCl2
*
[3H]DA [nM]
Sp
ec
ifi
c 
[3
H
]D
A 
U
pt
ak
e
(p
m
ol
/m
g 
pr
ot
ei
n/
m
in
.)
 
 53
 
Figure 17: 20 and 200nM [3H]DA uptake in SK-N-SH cells after 96 hour exposure to 10.0µM  
MnCl2.  Above values represent mean ± SEM of an N=4 run in duplicate.  The Bradford 
method was used to determine protein concentration so values could be reported as pmol/mg 
protein/ min.  A Bonferroni posttest calculated no significant treatment effects at either 20 or 
200nM [3H]DA (p>0.05 for both concentrations).  
 
  
 The Bonferroni post test conducted on the 96 hour uptake data determined there 
was not a significant difference due to treatment at either [3H]DA concentration 
examined (p>0.05 for both 20 and 200nM [3H]DA) (Figure 15). 
Table 6: Summary of Uptake Findings after treatment with  
10.0uM MnCl2 in SK-N-SH cells 
 20nM 200nM 
48 Control vs. 48 MnCl2  no significant difference significant difference (p<0.05)
96 Control vs. 96 MnCl2 no significant difference no significant difference 
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V. DISCUSSION 
 The heavy metals mercury and manganese can be found throughout the 
environment.  The acute toxic affects of these metals have been recognized for a long 
time, and therefore recommendations and precautions have been taken to limit or avoid 
exposure to these metals.  Because of these efforts, acute toxicity due to manganese or 
mercury is relatively rare in today’s world.  However, what is not as well documented or 
recognized are the possible effects of these metals when exposure occurs at low 
concentrations for extended time periods.  Because these metals are ever present with 
increasing exposure to the population, this study was designed to look at the effects of 
extended exposure to low concentrations of mercuric and manganese chlorides on 
dopamine transporter function.  The dopamine transporter is suspected to play a role in 
disease states affecting the dopaminergic system.  Because the dopaminergic system is 
responsible for the reward and locomotor responses among others, its proper functioning 
and how it is affected by exogenous toxins is important to understand. 
 The purpose of this study was to determine what effects extended, low dose 
mercuric and manganese chloride treatments have on the DAT functionality in the SK-N-
SH cell line.  Initial studies were aimed at finding the greatest concentration of metal that 
did not result in a reduction in cell viability.  These concentrations and time points were 
then analyzed for caspase-3/7 activity to determine if the cells were entering a slower 
death process, apoptosis, as this could factor into any effects detected from the metal 
treatments.  Subsequent assays were then more focused on the specific effects of 
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mercuric and manganese chloride on the dopamine transporter.  These studies measured 
cell expression, saturation binding, and uptake as specifically related to the dopamine 
transporter. 
 The overall findings from this study are as follows: sub-lethal concentrations for 
mercuric and manganese chlorides in the SK-N-SH cell line were identified that did not 
cause the cells to enter into apoptosis at either 48 or 96 hour time points.  Expression and 
functionality studies, [3H]GBR-12,935 binding and [3H]DA uptake assays indicated that 
low concentrations of mercuric chloride exerted an effect on the binding of [3H]GBR-
12,935 to the dopamine transporter and the [3H]DA uptake capabilities of this protein.  
Low levels of manganese chloride also caused changes on the ability of [3H]GBR-12,935 
to bind to the dopamine transporter as well as alterations in this transporter’s ability to 
uptake [3H]DA. 
V.A. LDH and Caspase-3/7 Assays 
 In order to determine how long term exposure to low concentrations of heavy 
metals affects the dopamine transporter, it was first necessary to determine the threshold 
mercuric and manganese chloride concentrations that would not reduce viability in the 
SK-N-SH cells when treatment times were increased up to 96 hours.  The initial 
concentrations chosen were selected from a review of the literature, and overt toxicity 
was determined using a lactate dehydrogenase (LDH) assay from Promega (Madison, 
WI).     
 LDH is an enzyme found in the cytosol and released when cells undergo lysis.  
Promega’s Cytotoxicity Assay kit detects the presence of LDH as indicated by a color 
change that is proportional to the amount of cell death that occurred in the sample.  In this 
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study, the amounts of LDH activity present in the samples were measured immediately at 
the end of the treatment time (spontaneous release) and after the remaining viable cells in 
the sample were lysed (total release).  By measuring both the spontaneous release and 
total release, calculations could be made to negate any difference in the number of cells 
per sample or between plates.   
 The concentrations chosen for analysis for mercuric chloride were 0.1, 1.0, 10.0, 
and 50.0µM.  A review of the literature uncovered only two studies reporting effects of 
mercury on SK-N-SH cells (Abdulla et al., 1995; Humphrey et al., 2005).  However, both 
studies looked at different mercury reagents (thimerosal or mercuric oxide) compared to 
this study.  Reported median effective concentrations (EC50), the concentration that 
caused an effect in half of the cells, from mercuric chloride cytotoxicity studies ranged 
from 3.49µM in SH-SY5Y neuroblastoma cells (Toimela & Tahti, 2004) to 70µM in 
BALB/c macrophages (Kim & Sharma, 2004).  The concentrations tested in this study 
either fell below or within this range. 
 From the LDH assay performed on the cells treated with mercuric chloride, an 
effect on cell viability was found that is dependent on concentration and time, as well as 
an interaction of the two.  In other words, not only was there a decrease in viability due to 
increasing exposure times and increasing metal concentrations individually, but when the 
effects of these variables were combined there was an even greater increase in cell death.  
While other studies have reported observing a concentration effect on cell viability 
(Parran et al., 2001; Olivieri et al., 2000), few studies have reported the effects of 
mercuric chloride on viability at time points extending beyond 48 hours.  Three studies 
were found reporting viability effects after 48 hour exposure times (Ben-Ozer et al., 
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2000; Kim & Sharma, 2004; Aleo et al., 2005).  The two studies reporting results up to 
72 hours had different findings.  In the study by Ben-Ozer et al., (2000) with U-937 
human monocyte-like cells, concentrations of 0.1 to 100µM mercuric chloride over 24-72 
hours were examined.  A decrease in viability due to concentration was observed, and a 
trend of decreased viability over time at 1µM was pointed out, however this later 
observation was slight and not statistically significant (Ben-Ozer et al., 2000).  The other 
study examining varying concentrations (3, 10 and 30µM) of mercuric chloride up to 72 
hours reported no effect on cell viability in Madin-Darby canine kidney cells at any of the 
concentrations or times tested (Aleo et al., 2005).  The third study reported no effect on 
viability after 96 hour exposure times with concentrations up to 20µM in macrophages 
(Kim & Sharma, 2004).  These different effects of mercury on cell viability emphasize 
the point that the physiological response to exposure depends on several factors, 
including the cell line being used. 
 For the viability assays using manganese chloride, concentrations of 1, 2.0, 5.0 
and 10.0µM were chosen for their effects on the SK-N-SH cell line.  A significant effect 
of concentration or time, and a synergistic effect of concentration and time were 
observed.  However, since statistical analysis determined only one point to be 
significantly different from control values (48hr exposure to 2µM manganese chloride), 
the effect is likely to be representative of the observed trends.  Therefore, 10.0µM 
manganese chloride at 48 and 96 hour treatment times was chosen to be examined for the 
remaining studies.  
 Unlike mercuric chloride, there are some studies reporting the effects of 
manganese chloride on the SK-N-SH cell line.  Two of these studies examined the effect 
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of increasing concentrations of manganese chloride on cell viability.  Keller et al., (2005) 
reported a concentration-dependent biphasic response after treating SK-N-SH cells for 48 
hours with manganese chloride, in concentrations ranging from 10.0µM to 3mM, with 
lower concentrations increasing viability and higher concentrations resulting in increased 
cell death.  The other study examining the effects of manganese chloride on SK-N-SH 
cells calculated an EC50 = 200µM after treating the cells with increasing concentrations 
from 10µM-1mM for 24 hours (Stredrick et al., 2004).  While it is not discussed in their 
report, the data showed a concentration effect on cell viability; as the concentration of 
manganese chloride exposure increased, cell viability decreased.  Both of the trends 
mentioned above, are more obvious trends compared to the current data, which is likely 
due to the larger range of concentrations examined in previous studies. 
 Before the specific effects of these metals on the dopamine transporter were 
examined, an assay was conducted to see if sub-toxic concentrations of the two metals 
caused the cells to enter apoptosis.  Promega’s Caspase-3/7 Assay was utilized to detect 
any changes in the activity of caspases-3 and -7 after 1µM HgCl2 and 10µM MnCl2 
treatment for 48 and 96 hours.  These caspases are activated during the “effector phase” 
of apoptosis which is immediately before the “cell degradation phase” and cell death 
(Honing and Rosenberg, 2000).  Therefore, measuring the activity of these caspases not 
only is an indication of cells in apoptosis, but also indicates that cell death is imminent. 
 The results from this study demonstrated that treatment of SK-N-SH cells with 
1.0µM HgCl2 for 48 hours did not result in an increase in the number of cells entering 
apoptosis as compared to the control group.  No significant difference in caspase activity 
was observed after the 96 hour exposure time either.  There was a slight increase in the 
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amount of fluorescence in both the control and mercury treated groups at 96 hours as 
compared to the 48 hours groups, however this difference was not significant.  It may be 
that the increase in fluorescence is due to a slight increase in caspase activity in the viable 
cells.  This would be expected and probably reflects increases in basal levels of caspase 
with increasing time.  To test this idea, the data from the caspase-3/7 assay was combined 
with the data from the LDH assay to analyze the ratio of unit of caspase-3/7 activity per 
viability (as reflected in LDH activity).  Statistical analysis of the ratios determined there 
was not a difference in the means of the control and mercury treatment groups at either 
48 or 96 hours, indicating there is no change in the amount of caspase-3/7 activity in the 
viable cells present in the sample. 
 For the cells treated with 10.0µM MnCl2, little difference was observed in 
caspase-3/7 activity between the control and treatment groups at either the 48 or 96 hour 
exposure times.  Again, the ratio of caspase-3/7 activity was paired to the corresponding 
values of viability after manganese chloride treatment and statistically analyzed for any 
differences from control values.  When control values were compared to manganese 
chloride treatments, there was a significant difference detected in the unit caspase-3/7 
activity per viability, suggesting there may be an increase in the activities of caspases-3 
and -7 in the remaining cells.  Further statistical analysis, however, did not calculate a 
difference between control and manganese chloride groups at 48 or 96 hours.   
 It was concluded from the LDH and Caspase-3/7 assays that mercuric chloride is 
a more robust toxin compared to manganese chloride at the concentrations and times 
examined.  This conclusion supports the idea that mercuric chloride would be able to 
exert its effects more quickly than manganese chloride after exposure, predicting that 
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neurological symptoms would appear sooner in patients exposed to mercury as opposed 
to those exposed to manganese. 
V.B. DAT Functional Assays 
 Because the number of dopamine transporters present on the cell plays a part in 
how well dopamine is taken up into the cell, analyzing how its presence is affected by 
toxins is just as important as studying the actual function of substrate movement by this 
protein.  The selectivity of [3H]GBR-12,935 binding to the dopamine transporter makes it 
a useful tool for labeling and studying the presence and functioning of the transporter.  
[3H]GBR-12,935 binding to the dopamine transporter was used to determine if the heavy 
metal treatments had an effect on (1) the amount of DAT being expressed in cells (Bmax) 
and (2) the binding affinity (KD) of the transporter.  Alterations in the amount of the DAT 
being expressed by the cells exposed to heavy metal was detected using a one-point 
binding assay with 4nM [3H]GBR-12,935, while DAT affinity and capacity kinetics were 
evaluated using increasing concentrations (1, 2.5, 5, 10, 25, 50nM) of [3H]GBR-12,935.    
 Another aspect of dopamine transporter function is the actual uptake of dopamine.  
This was measured after mercuric and manganese chloride exposure.  Both low (20nM) 
and high (200nM) concentrations of [3H]DA were utilized in the uptake studies so that 
any shift in uptake due to these metals could be detected.  To reduce variability, half of 
the flask of cells treated for the uptake assay were set aside and used for the saturation 
binding curve assays mentioned in the preceding paragraph.   
V.B.i.  Mercuric chloride effects on DAT functionality  
 The results from the single-point (4nM) [3H]GBR-12,935 binding assay indicated 
1.0µM mercuric chloride treatment does not affect the expression of DAT on SK-N-SH 
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cells when compared to control values.  Neither was there a change in DAT expression 
from 48 to 96 hour treatment after exposure to this metal.  Statistical analysis of the data 
generated from the saturation binding curve assays revealed that there was no difference 
in the binding affinity of [3H]GBR-12,935 for the DAT after 48 or 96 hour exposure to 
mercuric chloride when compared to corresponding control values.  There was also no 
significant difference detected for binding capacity after mercuric chloride treatment at 
48 and 96 hours.  However, there was a trend of increased binding capacity when 
compared to control values after 48 hour exposure, and a slight decrease in binding 
capacity after 96 hour exposure when compared to the corresponding control values.  
There was a significant difference in binding capacity due to mercuric chloride treatment 
between the 48 and 96 hours exposure times.  These results demonstrate that the number 
of DAT binding sites decrease from 48 to 96 hours after mercuric chloride treatment. 
 Previous studies have reported effects on DAT binding and DA uptake after acute 
exposure to mercury.  Cao et al. (1989) reported an inhibition of [3H]cocaine binding and 
[3H]DA uptake by the DAT following inorganic mercury exposure in bovine and rat 
striata.  From their results, they hypothesized the existence of one or more thiol groups on 
the dopamine transporter are important for binding and uptake functions (Cao et al., 
1989).  Richfield (1993) also reported Hg2+ ions reduced binding of [3H]GBR-12,935 to 
the DAT.  Short term mercury exposure (ten minutes to an hour) effects on the DAT 
resulted in low (3µM) concentrations stimulating the binding of two other dopamine 
uptake inhibitors, [3H]mazindol and [3H]WIN-35,428, while higher concentrations (30-
100µM) inhibited binding of these radioligands to the DAT (Wu et al., 1997).  Another 
study also found this biphasic effect on DAT binding after mercuric chloride exposure 
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with [3H]methylphenidate binding in striatal tissue exposed to increasing concentrations 
(0.05-1000µM) for thirty minutes (Schweri, 1994).  Schweri (1994) observed both the 
affinity and Bmax of [3H]methylphenidate binding to be altered at the higher mercury 
concentrations (both reduced), while only the affinity was affected (increased) at lower 
concentrations. 
 Mercury was also reported to inhibit [3H]DA uptake after acute exposure.  Cao et 
al., (1989) reported in the same study as their binding experiments, an inhibition of 
[3H]DA uptake following inorganic mercury exposure in bovine and rat striata.  Another 
study, however, determined there was no effect of HgCl2 on synaptosomal [3H]DA 
uptake (Schweri, 1994; Komulainen & Tuomisto, 1981).  Rajanna and Hobson (1985) 
reported a concentration-dependent reduction in [3H]DA uptake when compared to 
control following exposure to mercuric chloride, with an initial significant decrease 
occurring after a five minute incubation with 1.0µM. 
 The current study noted an effect of exposure time, [3H]DA concentration, and a 
synergistic interaction of exposure time and [3H]DA concentration on the uptake of 
[3H]DA through the dopamine transporter.  After 48 hour exposure to mercuric chloride, 
a statistically significant decrease in uptake was observed in comparison to the control 
groups.  96 Hour exposure to mercuric chloride did not cause a significant effect on 
[3H]DA uptake, however a increase in uptake when compared to control values was 
observed.    
 Combining the [3H]DA uptake results with the [3H]GBR-12,935 saturation 
binding studies would suggest that HgCl2 at low concentrations and longer exposure 
times does affect the DAT functioning.  As was seen after 48 hour mercuric chloride 
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exposure, an increase in binding capacity with a decrease in uptake through the DAT was 
observed.  This was followed by a decrease in binding capacity and an increase in uptake 
when compared to the control groups after 96 hour exposures.  These effects could 
possibly be due to a direct interaction of mercury with the cysteine residues on the 
transporter since mercury does have a high affinity for thiol groups.  Another possible 
explanation is that mercury may interfere with or alter the N-glycosylation sites on the 
large extracellular loop of DAT.  As mentioned earlier in the DAT section of the 
literature review, previous studies have reported the importance of glycosylation of the 
DAT.  Torres et al. (2003) and Li et al. (2004), looking at the effects of the removal of 
one or more of the glycosylation sites have reported an affect on the binding capacity of 
DAT with no (Torres et al., (2003)) or little (Li et al., (2004)) effect on the affinity of this 
transporter.  In other words, this transporter while still expressed in the cells has 
decreased ability for DA uptake.  Results from [3H]GBR-12,935 binding and [3H]DA 
uptake as described above, suggests this may be a possible mechanism of mercury on the 
DAT. 
V.B.ii. Manganese chloride effects on DAT functionality  
 In this study, it was determined 10.0µM manganese chloride treatment, when 
compared to corresponding control values, had no effect on the single-point (4nM) 
[3H]GBR-12,935 binding to the DAT, nor did this metal significantly affect the binding 
affinity or capacity of the DAT as determined through [3H]GBR-12,935 saturation curve 
binding.  There was a decrease in binding capacity from the 48 to 96 hour exposure 
times; however, this difference was not statistically significant from control values. 
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 Increased [3H]DA uptake was observed after manganese chloride exposure in 
comparison to control groups.  This increase occurred at 200nM [3H]DA after 48 and 96 
exposure times, however the increase was determined statistically significant only after 
48 hour exposure times.  As was detected with mercuric chloride, there was an overall 
decrease in uptake experienced by control and groups treated with manganese chloride 
from the 48 to 96 hour time points. 
 In vivo effects of manganese on DAT binding has been reported in several studies.  
Reichel et al. (2006) reported that early exposure of rats to manganese altered DAT 
function once the rat reached adulthood.  They found a decrease in [3H]GBR-12,935 
striatal DAT binding in the rats without an effect on DAT affinity, but a significant 
decrease in binding capacity (Reichel et al., 2006).  Huang et al. (2003), also found that 
DAT binding was decreased in patients after chronic manganese exposure when 
compared to control patients.  Chronic manganese exposure in monkeys also has been 
reported to cause a reduction in [3H]mazindol binding to DAT in the caudate nucleus and 
putamen after chronic exposure (Eriksson et al., 1992).    
 While it appears there is supportive data that chronic manganese exposure reduces 
DAT binding, the effect of dopamine uptake via the DAT after chronic manganese 
exposure is not as clear.  Results from [3H]DA uptake studies have reported both 
increases and decreases in DAT functioning from animal studies (Reichel et al., 2006).  
Lai et al., (1982) reported a decrease in [3H]DA uptake after 1mg MnCl2·H2O/ml for 70 
to 90 days.  This is in contrast to the increase in [3H]DA uptake reported by Leung et al 
(1982) after 10 mg MnCl2·H2O/ml for 80 days.  The differences seen between these two 
studies are likely due to the increase in MnCl2 concentration.  Higher concentrations may 
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result in upregulation of DAT as a compensatory safety mechanism.  The concentrations 
in these in vivo studies are higher than the ones used in the current study.  However, 
caution is needed in comparing the manganese concentrations between animal and in 
vitro studies.  It is difficult to extrapolate the concentrations from in vitro synaptic to 
corresponding in vivo whole tissue studies.  It is unknown to what extent the metals 
concentrate in the synaptic regions in the animal studies. 
 The combination of uptake and binding results after manganese chloride exposure 
found in this study suggest that manganese at low concentrations over 48-96 hours does 
affect the DAT.  It was seen that uptake was increased after 48 hour exposure time with 
no difference seen in binding capacity in comparison with control values.  96 Hour 
exposure to manganese when compared to control also demonstrated an increase in 
[3H]DA uptake with a little decrease in binding capacity.  It is believed that manganese 
exerts much of its toxic effects through oxidative stress (Migheli et al., 1999).  The 
results in this study would support this theory as oxidation from manganese could have 
been reduced due to the antioxidant substrates in the solvent used as a vehicle for 
manganese chloride. 
V.VI. Summary 
 Because the dopamine transporter is specifically targeted by certain neurotoxins, 
it is already considered to be highly susceptible to alterations in the dopaminergic system.  
The chances of an individual developing Alzheimer’s disease or Parkinson’s disease 
increases when this transporter is affected by long term exposure to low concentrations of 
heavy metals such as mercury and manganese.  Pifl et al. (2004) suggested the idea of a 
second noxious factor causing a pre-condition to develop into an overt symptomology.  It 
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is possible that while these low concentrations of mercury or manganese by themselves 
are not detrimental, there may be pre-disposing factors such as additional neurotoxin 
exposure or a compromised dopaminergic system that will result in additive or 
synergistic effects, thereby allowing these low levels of metals to result in a full-fledged 
disease state.  
 Mercury and manganese are both ubiquitous in the environment, and therefore 
exposure is inevitable.  Exposure routes to these metals can occur through many routes 
including natural, occupational, and accidental.  Advisories and regulations have been 
suggested to limit population exposure to these metals, however it is unknown if these 
levels are low enough to protect individuals from developing toxicity after extended 
exposure.  Therefore, further research into the effects of extended exposure to low 
concentrations of mercury and manganese should be conducted. 
V.V. Future Studies 
 Further studies to be conducted will examine if and how these concentrations of 
mercuric chloride or manganese chloride at the 96 hour time point affects the intracellular 
trafficking of the DAT and whether exposure to these metals results in the transporter to 
be more rapidly degraded or recycled after leaving the cell surface.  This study could also 
be replicated in an in vivo model to determine if [3H]DA uptake, DAT binding, and DAT 
trafficking are affected the same way by these metal concentrations and time points.
 Another aspect that should be examined is the effects of low levels and long term 
exposure to methyl mercury and manganese sulfate, more potent and damaging forms of 
mercury and manganese than the metal salts used in this study.  The effects of the 
combination of these two metals on the DAT would also be an interesting and pertinent 
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study to undertake.  Since both metals are ubiquitous in nature, it is unlikely an individual 
is only exposed to one or the other of these metals.     
V.IV. Summary of Conclusions 
 
• [3H]GBR-12,935 saturation binding studies indicated there was a change in the binding 
capacity (Bmax) of DAT after extended exposure to 1.0µM mercuric chloride treatment, 
with no statistically significant change in DAT affinity (KD).  10.0µM manganese 
chloride did not statistically affect Bmax or KD values at these same exposure times. 
• [3H]DA uptake studies determined there was a significant change in uptake in SK-N-SH 
cells due to exposure with 1.0µM HgCl2 or 10.0µM MnCl2 after 48 hours, with HgCl2 
decreasing uptake and MnCl2 increasing uptake in comparison to control groups.  
[3H]DA uptake after 96 hour exposure to these metals did not result in a difference in 
uptake in comparison to respective control values.   
• HgCl2 may result in direct alteration of DAT and DA function.  This is most likely due 
to interactions at thiol groups and could involve changes in DAT glycosylation or other 
intracellular changes. 
•MnCl2 appears to affect DAT and DA function indirectly.  In vivo studies have shown a 
more robust change in DAT and this could be due to effects on other systems.  
Upregulation of DAT would result in increased dopamine uptake and metabolism by 
MAO leading to formation of H2O2 and free radicals, thus slowly damaging the cell from 
the inside. 
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Scope and Method of Study: The purpose of this study was to investigate the effects of  
low concentrations of mercuric (II) and manganese (II) chloride on the dopamine  
transporter (DAT) functioning through radioligand uptake and binding studies.  
SK-N-SH cells were utilized for this study, and the effect of low concentrations 
on cell viability was examined using LDH assays and caspase-3/7 activity to 
establish cell death or apoptotic activity, respectively.  [3H]Dopamine uptake and 
[3H]GBR-12,935 binding saturation curve studies were conducted to establish the 
effects low concentrations had on DAT functioning. 
 
Findings and Conclusions: The results of the LDH assay determined that there was a  
significant effect of time (p=0.0069), concentration (p<0.0001), and time X 
concentration interaction (p<0.0001) on cell viability when SK-N-SH cells were 
treated for 24-96 hours with HgCl2 (0.1-50µM).  Treatments of MnCl2 at 
concentrations of 1.0-10.0µM for 24-96 hours also resulted in a significant effect 
of time (p<0.0001), concentration (p=0.0003) and time X concentration 
interaction (p<0.0001) on the SK-N-SH cell line viability.  Caspase-3/7 activity 
was not significantly different in either the 1.0µM HgCl2 (p=0.3255) or 10.0µM 
MnCl2 (p=0.1670) groups compared to controls.  [3H]GBR-12,935 binding also 
was not significantly different in the 1.0µM HgCl2 (p=0.7761) or 10.0µM MnCl2 
(p=0.9966) treatments when compared to control.  [3H]GBR-12,935 saturation 
binding curve studies revealed there was no significant difference in Bmax or KD 
values following 48 or 96 hour HgCl2 (p>0.05) or MnCl2 (p>0.05) exposure when 
compared to control values.  However, there was a trend of increased Bmax after 
48 hour exposure to HgCl2.  [3H]DA uptake assays used to measure functionality 
determined there was a significant difference between HgCl2 (decreased uptake, 
p<0.01) and MnCl2 (increased uptake; p<0.05) in comparison to control values 
after 48 hours.  Uptake values were not different between treatment and control 
groups at 96 hours.  From these studies, it is concluded that DAT functionality is 
affected by 1.0µM HgCl2 or 10.0µM MnCl2 treatment in SK-N-SH cells.  These 
effects may be due to direct or indirect effects of the metals on the DAT.  
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